Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
暂无分享,去创建一个
Gilberto Fisone | Maryka Quik | M. Angela Cenci | Wassilios G. Meissner | Laurent Groc | A. Jon Stoessl | Fabrizio Gardoni | Alan R. Crossman | Nicola Simola | Micaela Morelli | Riccardo Brambilla | Stefania Fasano | B. Picconi | W. Ko | E. Bézard | G. Fisone | D. Guehl | W. Meissner | M. Morelli | A. Crossman | S. Fox | F. Tison | L. Groc | M. Cenci | M. Bourdenx | M. Morari | S. Fasano | R. Brambilla | U. Kang | M. Quik | E. Gurevich | Matthieu F. Bastide | P. Fernagut | M. Feyder | V. Francardo | C. Alcacer | Yunmin Ding | A. Stoessl | M. Engeln | S. Navailles | P. Deurwaerdère | N. Simola | Maria-Cruz Rodriguez | M. Mellone | F. Gardoni | E. Tronci | K. Steece-Collier | M. Carta | Un Jung Kang | Dominique Guehl | Eugenia V. Gurevich | François Tison | Pierre-Olivier Fernagut | Michel Engeln | Manolo Carta | Barbara Picconi | Veronica Francardo | Yunmin Ding | Erwan Bézard | Michael Feyder | Cristina Alcacer | Mathieu Bourdenx | Sylvia Navailles | Philippe De Deurwaerdère | Wai Kin D. Ko | Maria-Cruz Rodriguez | Michele Morari | Manuela Mellone | Elisabetta Tronci | Kathy Steece-Collier | Susan Fox | M. Bastide | W. K. D. Ko | Veronica Francardo
[1] B. Cormand,et al. Levodopa‐induced dyskinesias in tyrosine hydroxylase deficiency , 2013, Movement disorders : official journal of the Movement Disorder Society.
[2] R. Arai,et al. Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenousl-DOPA in the rat, with reference to the involvement of aromaticl-amino acid decar☐ylase , 1994, Brain Research.
[3] W Zieglgänsberger,et al. [3h]-nociceptin ligand-binding and nociceptin opioid receptor mrna expression in the human brain , 2003, Neuroscience.
[4] J. Dostrovsky,et al. Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease. , 2001, Journal of neurophysiology.
[5] C. Marsden,et al. Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease , 1995, Neuroscience.
[6] F. Mastaglia,et al. Globus pallidus stimulation improves both motor and nonmotor aspects of quality of life in advanced Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.
[7] M. Tyers,et al. A new family of regulators of G-protein-coupled receptors? , 1996, Current Biology.
[8] W. Poewe,et al. The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[9] C. Lüscher,et al. D1R/GluN1 complexes in the striatum integrate dopamine and glutamate signalling to control synaptic plasticity and cocaine-induced responses , 2014, Molecular Psychiatry.
[10] W. Olson,et al. Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial. , 1997, The American journal of medicine.
[11] U. Ungerstedt. Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. , 1971, Acta physiologica Scandinavica. Supplementum.
[12] E. Bézard,et al. Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. , 2004, European journal of pharmacology.
[13] D. Centonze,et al. d-Aspartate Prevents Corticostriatal Long-Term Depression and Attenuates Schizophrenia-Like Symptoms Induced by Amphetamine and MK-801 , 2008, The Journal of Neuroscience.
[14] R. Todd,et al. Dynamic Changes in Striatal Dopamine D2 and D3 Receptor Protein and mRNA in Response to 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Denervation in Baboons , 1996, The Journal of Neuroscience.
[15] R. Huganir,et al. Control of GluR1 AMPA Receptor Function by cAMP-Dependent Protein Kinase , 2000, The Journal of Neuroscience.
[16] D. Riche,et al. A primate model of Huntington's disease: Behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon , 1990, Experimental Neurology.
[17] B. Bloch,et al. D1 and D2 dopamine receptor gene expression in the rat striatum: Sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAS in distinct neuronal populations of the dorsal and ventral striatum , 1995, The Journal of comparative neurology.
[18] M. Barrot,et al. ΔFosB: A sustained molecular switch for addiction , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[19] M. Beal,et al. Inhibition of neuronal nitric oxide synthase prevents MPTP–induced parkinsonism in baboons , 1996, Nature Medicine.
[20] R. Maj,et al. Safinamide , 2006, Neurology.
[21] J. Henley,et al. Lateral Diffusion Drives Constitutive Exchange of AMPA Receptors at Dendritic Spines and Is Regulated by Spine Morphology , 2006, The Journal of Neuroscience.
[22] [L-dopa in Parkinson's syndrome]. , 1971 .
[23] Theodore G. Wensel,et al. RGS Expression Rate-Limits Recovery of Rod Photoresponses , 2006, Neuron.
[24] J. Brotchie,et al. The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future. , 2010, Progress in brain research.
[25] H. Miwa,et al. Effects of T-type calcium channel blockers on a parkinsonian tremor model in rats , 2011, Pharmacology Biochemistry and Behavior.
[26] K. Dalby,et al. Haloperidol and Clozapine Differentially Affect the Expression of Arrestins, Receptor Kinases, and Extracellular Signal-Regulated Kinase Activation , 2008, Journal of Pharmacology and Experimental Therapeutics.
[27] T. Chase,et al. NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats , 2004, Neuropharmacology.
[28] M. Stacy,et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease , 2008, Neurology.
[29] Paul Greengard,et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA–induced dyskinesia , 2003, Nature Neuroscience.
[30] A. Holman. Impulse Control Disorder Behaviors Associated with Pramipexole Used to Treat Fibromyalgia , 2009, Journal of Gambling Studies.
[31] S. L. Nicholson,et al. Topiramate reduces levodopa‐induced dyskinesia in the MPTP‐lesioned marmoset model of Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.
[32] Andrew J Lees,et al. Pathological gambling in Parkinson's disease—a review of the literature , 2011, Movement disorders : official journal of the Movement Disorder Society.
[33] J. Brotchie,et al. Serotonin and Parkinson's disease: On movement, mood, and madness , 2009, Movement disorders : official journal of the Movement Disorder Society.
[34] Qin Li,et al. Synaptic recruitment of AMPA glutamate receptor subunits in levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate , 2010, Synapse.
[35] M. Garret,et al. Distinct Cellular and Subcellular Distributions of G Protein-Coupled Receptor Kinase and Arrestin Isoforms in the Striatum , 2012, PloS one.
[36] E. Bézard,et al. Endogenous morphine-like compound immunoreactivity increases in parkinsonism. , 2011, Brain : a journal of neurology.
[37] P. Petersson,et al. Levodopa-Induced Dyskinesia Is Strongly Associated with Resonant Cortical Oscillations , 2012, The Journal of Neuroscience.
[38] M. Nirenberg. Dopamine Agonist Withdrawal Syndrome: Implications for Patient Care , 2013, Drugs & Aging.
[39] E. Bézard,et al. Levodopa–induced dyskinesias in the absence of nigrostriatal degeneration , 2013, Movement disorders : official journal of the Movement Disorder Society.
[40] Y. Kawamoto,et al. RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy , 2011, Dermatology research and practice.
[41] A. Lees. Levodopa Substitution: The Gold Standard , 1994 .
[42] Talia N. Lerner,et al. RGS4 Is Required for Dopaminergic Control of Striatal LTD and Susceptibility to Parkinsonian Motor Deficits , 2012, Neuron.
[43] P. Blanchet,et al. Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[44] Adam T. Brewer,et al. Effects of pramipexole on impulsive choice in male wistar rats. , 2010, Experimental and clinical psychopharmacology.
[45] C. Sampaio,et al. Evidence-based medicine (EBM) applied to Parkinson's disease treatment. , 2002, Parkinsonism & related disorders.
[46] L. Grégoire,et al. Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys. , 2000, European journal of pharmacology.
[47] C. Aoki,et al. Beta-arrestin2, a novel member of the arrestin/beta-arrestin gene family. , 1992, The Journal of biological chemistry.
[48] P. Pollak,et al. Multifocal enhancing cortical lesions in a patient with Churg-Strauss syndrome , 2008, Neurology.
[49] Y. Agid,et al. Levodopa‐induced dyskinesias in Parkinson's disease: Is sensitization reversible? , 2000 .
[50] A. Lees,et al. Recognition of a dopamine replacement therapy dependence syndrome in Parkinson's disease: a pilot study. , 2004, Drug and alcohol dependence.
[51] Marina R. Picciotto,et al. It is not “either/or”: Activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood , 2008, Progress in Neurobiology.
[52] F. Verhey,et al. Serotonergic mechanisms in Parkinson’s disease: opposing results from preclinical and clinical data , 2005, Journal of Neural Transmission.
[53] D. Riche,et al. A primate model of Huntington's disease: cross-species implantation of striatal precursor cells to the excitotoxically lesioned baboon caudate-putamen , 2004, Experimental Brain Research.
[54] R. Challiss,et al. Imaging of Muscarinic Acetylcholine Receptor Signaling in Hippocampal Neurons: Evidence for Phosphorylation-Dependent and -Independent Regulation by G-Protein-Coupled Receptor Kinases , 2004, The Journal of Neuroscience.
[55] E. Birket-Smith,et al. ABNORMAL INVOLUNTARY MOVEMENTS INDUCED BY ANTICHOLINERGIC THERAPY , 1974, Acta neurologica Scandinavica.
[56] B. Averbeck,et al. Novelty seeking behaviour in Parkinson's disease , 2011, Neuropsychologia.
[57] A. Benabid,et al. Effects of magnetic resonance imaging in patients with implanted deep brain stimulation systems. , 2010, Journal of neurosurgery.
[58] Yoshiaki Washio,et al. Direct small-molecule kinase activation: Novel approaches for a new era of drug discovery. , 2009, Current opinion in drug discovery & development.
[59] Houeto Jean-Luc. [Parkinson's disease]. , 2022, La Revue du praticien.
[60] N. Pavón,et al. ERK Phosphorylation and FosB Expression Are Associated with L-DOPA-Induced Dyskinesia in Hemiparkinsonian Mice , 2006, Biological Psychiatry.
[61] P. Seeman,et al. Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: Implications for positron emission tomography of the human brain , 1989, Synapse.
[62] A. Björklund,et al. Intrastriatal implants of mesencephalic cell suspensions in weaver mutant mice: ultrastructural relationships of dopaminergic dendrites and axons issued from the graft , 2004, Experimental Brain Research.
[63] J. Brotchie,et al. The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[64] A. Benabid,et al. Improvement of levodopa induced dyskinesias by thalamic deep brain stimulation is related to slight variation in electrode placement: possible involvement of the centre median and parafascicularis complex , 1999, Journal of neurology, neurosurgery, and psychiatry.
[65] L. Tremblay,et al. Impairment of context-adapted movement selection in a primate model of presymptomatic Parkinson's disease. , 2003, Brain : a journal of neurology.
[66] L. Grégoire,et al. Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys. , 2013, Parkinsonism & related disorders.
[67] S. Snyder,et al. Cloning and expression of an adenylyl cyclase localized to the corpus striatum , 1993, Nature.
[68] Erwan Bezard,et al. Modeling Parkinson's disease in primates: The MPTP model. , 2012, Cold Spring Harbor perspectives in medicine.
[69] J. McGinty,et al. Regulator of G-Protein Signaling 4 Interacts with Metabotropic Glutamate Receptor Subtype 5 in Rat Striatum: Relevance to Amphetamine Behavioral Sensitization , 2007, Journal of Pharmacology and Experimental Therapeutics.
[70] J. Baraban,et al. The EGR family of transcription-regulatory factors: progress at the interface of molecular and systems neuroscience , 1999, Trends in Neurosciences.
[71] U. Ungerstedt,et al. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. , 1971, Acta physiologica Scandinavica. Supplementum.
[72] M. Morelli,et al. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6‐hydroxydopamine‐lesioned rats , 2001, Synapse.
[73] R. Roth,et al. Differential responsiveness to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in sub-regions of the primate substantia nigra and striatum. , 1987, Life sciences.
[74] C. Gerfen,et al. Differences between Dorsal and Ventral Striatum in Drd1a Dopamine Receptor Coupling of Dopamine- and cAMP-Regulated Phosphoprotein-32 to Activation of Extracellular Signal-Regulated Kinase , 2008, The Journal of Neuroscience.
[75] Nicola Simola,et al. The 6-Hydroxydopamine model of parkinson’s disease , 2007, Neurotoxicity Research.
[76] G. Fisone,et al. Dopamine Signaling Leads to Loss of Polycomb Repression and Aberrant Gene Activation in Experimental Parkinsonism , 2014, PLoS genetics.
[77] P. Calabresi,et al. Direct and indirect pathways of basal ganglia: a critical reappraisal , 2014, Nature Neuroscience.
[78] P. Gubellini,et al. Chronic high‐frequency stimulation of the subthalamic nucleus and L‐DOPA treatment in experimental parkinsonism: effects on motor behaviour and striatal glutamate transmission , 2006, The European journal of neuroscience.
[79] W. Ko,et al. Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson’s disease , 2015, Neuroscience.
[80] J. Langston,et al. Enhanced striatal opioid receptor-mediated G-protein activation in l-dopa-treated dyskinetic monkeys , 2005, Neuroscience.
[81] S. Salvadori,et al. UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor. , 2006, CNS drug reviews.
[82] Daniel B. McClatchy,et al. Functional specialization of β-arrestin interactions revealed by proteomic analysis , 2007, Proceedings of the National Academy of Sciences.
[83] J. Langston,et al. Levodopa induces dyskinesias in normal squirrel monkeys , 2001, Annals of neurology.
[84] Susan H. Fox,et al. l-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease , 2012, Neuropharmacology.
[85] MPTP treatment increases expression of pre-pro-nociceptin/orphanin FQ mRNA in a subset of substantia nigra reticulata neurons , 2010, Neuroscience.
[86] Robert J. Witte,et al. Magnetic Resonance Imaging and Deep Brain Stimulation , 2002, Neurosurgery.
[87] E. Bézard,et al. Double-dissociation of the catecholaminergic modulation of synaptic transmission in the oval bed nucleus of the stria terminalis. , 2011, Journal of neurophysiology.
[88] A. Björklund,et al. l-DOPA-Induced Dyskinesia in the Intrastriatal 6-Hydroxydopamine Model of Parkinson's Disease: Relation to Motor and Cellular Parameters of Nigrostriatal Function , 2002, Neurobiology of Disease.
[89] P. Greengard. The neurobiology of slow synaptic transmission. , 2001, Science.
[90] M. Beal,et al. Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase , 1999, Brain Research.
[91] Hartwig R. Siebner,et al. Abnormal dopaminergic modulation of striato-cortical networks underlies levodopa-induced dyskinesias in humans , 2015, Brain : a journal of neurology.
[92] J. Benovic,et al. Altered expression and subcellular distribution of GRK subtypes in the dopamine‐depleted rat basal ganglia is not normalized by l‐DOPA treatment , 2008, Journal of neurochemistry.
[93] M. Quik,et al. α6β2* and α4β2* Nicotinic Acetylcholine Receptors As Drug Targets for Parkinson's Disease , 2011, Pharmacological Reviews.
[94] J. Deniau,et al. Disinhibition as a basic process in the expression of striatal functions , 1990, Trends in Neurosciences.
[95] D. Brooks,et al. An Open-Label, Positron Emission Tomography Study to Assess Adenosine A2A Brain Receptor Occupancy of Vipadenant (BIIB014) at Steady-State Levels in Healthy Male Volunteers , 2010, Clinical neuropharmacology.
[96] M. Baba,et al. Upregulation of striatal adenosine A2A receptor mRNA in 6‐hydroxydopamine‐lesioned rats intermittently treated with L‐DOPA , 2004, Synapse.
[97] H. Reichmann,et al. Levetiracetam for levodopa-induced dyskinesia in Parkinson’s disease: a randomized, double-blind, placebo-controlled trial , 2010, Journal of Neural Transmission.
[98] O. Hornykiewicz,et al. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. , 1960, Parkinsonism & related disorders.
[99] Pardeep Singh,et al. Striatal Cholinergic Cell Ablation Attenuates l-DOPA Induced Dyskinesia in Parkinsonian Mice , 2014, The Journal of Neuroscience.
[100] F. Gasparini,et al. Metabotropic Glutamate Receptors for Parkinson's Disease Therapy , 2013, Parkinson's disease.
[101] D. Erlij,et al. l-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata , 2011, Neurobiology of Disease.
[102] Yen F. Tai,et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission , 2006, Annals of neurology.
[103] L. Grégoire,et al. Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms. , 2004, Parkinsonism & related disorders.
[104] Daniel Choquet,et al. New Concepts in Synaptic Biology Derived from Single-Molecule Imaging , 2008, Neuron.
[105] J. Benovic,et al. β-Arrestin acts as a clathrin adaptor in endocytosis of the β2-adrenergic receptor , 1996, Nature.
[106] A. Mushegian,et al. The Origin and Evolution of G Protein-Coupled Receptor Kinases , 2012, PloS one.
[107] A. Aristieta,et al. Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in l-DOPA-treated rats , 2014, Neuropharmacology.
[108] A. Lees,et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD , 2008, Neurology.
[109] J. C. Stoof,et al. Priming with L-DOPA differently affects dynorphin and substance P mRNA levels in the striatum of 6-hydroxydopamine-lesioned rats after challenge with dopamine D1-receptor agonist. , 1998, Brain research. Molecular brain research.
[110] G. Breese,et al. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. , 1987, The Journal of pharmacology and experimental therapeutics.
[111] D. Segal. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) , 2010 .
[112] E. Wolf,et al. Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[113] E. Bézard,et al. Levodopa gains psychostimulant‐like properties after nigral dopaminergic loss , 2013, Annals of neurology.
[114] L. Brandenburg,et al. Role of receptor internalization in the agonist‐induced desensitization of cannabinoid type 1 receptors , 2008, Journal of neurochemistry.
[115] R. Bakay,et al. Delivery of neurturin by AAV2 (CERE‐120)‐mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP‐treated monkeys , 2006, Annals of neurology.
[116] G. Di Chiara,et al. Agonist-induced homologous and heterologous sensitization to D-1- and D-2-dependent contraversive turning. , 1987, European journal of pharmacology.
[117] J. Drouin,et al. Striatal neuroadaptation and rescue of locomotor deficit by l‐dopa in aphakia mice, a model of Parkinson's disease , 2006, Journal of neurochemistry.
[118] F. Monsma,et al. Structure-Activity Relationship Studies on the Novel Neuropeptide Orphanin FQ* , 1996, The Journal of Biological Chemistry.
[119] Hartwig R. Siebner,et al. The acute brain response to levodopa heralds dyskinesias in Parkinson disease , 2014, Annals of neurology.
[120] A. Strafella,et al. Dopamine Agonists Diminish Value Sensitivity of the Orbitofrontal Cortex: A Trigger for Pathological Gambling in Parkinson's Disease? , 2009, Neuropsychopharmacology.
[121] M. Morari,et al. Amantadine attenuates levodopa‐induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels , 2011, Journal of neurochemistry.
[122] C. Marsden,et al. COMPLICATED RESPONSE FLUCTUATIONS IN PARKINSON'S DISEASE: RESPONSE TO INTRAVENOUS INFUSION OF LEVODOPA , 1982, The Lancet.
[123] M. Cenci. Dopamine dysregulation of movement control in l-DOPA-induced dyskinesia , 2007, Trends in Neurosciences.
[124] C. Goetz,et al. Hallucinations in Parkinson disease in the prelevodopa era , 2006, Neurology.
[125] Jian Wang,et al. Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD , 2001, Neurology.
[126] David R Williams,et al. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study , 2005, The Lancet Neurology.
[127] L. Grégoire,et al. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in l-DOPA-treated parkinsonian monkeys , 2013, Neuropharmacology.
[128] G. Bernardi,et al. Loss of Muscarinic Autoreceptor Function Impairs Long-Term Depression But Not Long-Term Potentiation in the Striatum , 2008, The Journal of Neuroscience.
[129] A. Björklund,et al. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. , 2000, Brain : a journal of neurology.
[130] S. Hitchcock,et al. Enhanced histamine H2 excitation of striatal cholinergic interneurons in L-DOPA-induced dyskinesia , 2015, Neurobiology of Disease.
[131] E. Bézard,et al. Levetiracetam Interferes With the l-Dopa Priming Process in MPTP-Lesioned Drug-Naive Marmosets , 2004, Clinical neuropharmacology.
[132] P. Worley,et al. The Immediate Early Gene Arc/Arg3.1: Regulation, Mechanisms, and Function , 2008, The Journal of Neuroscience.
[133] A. Björklund,et al. Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease , 2012, Experimental Neurology.
[134] A. Faure,et al. Lesion to the Nigrostriatal Dopamine System Disrupts Stimulus-Response Habit Formation , 2005, The Journal of Neuroscience.
[135] P. Spano,et al. Reciprocal Regulation of Dopamine D1 and D3 Receptor Function and Trafficking by Heterodimerization , 2008, Molecular Pharmacology.
[136] P. Jenner,et al. Chronic L‐DOPA administration induces dyskinesias in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmoset (Callithrix jacchus) , 1995, Movement disorders : official journal of the Movement Disorder Society.
[137] K. Black,et al. Altered thalamic response to levodopa in Parkinson's patients with dopa-induced dyskinesias. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[138] T. Aziz,et al. Lesion of the subthalamic nucleus for the alleviation of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐induced parkinsonism in the primate , 1991, Movement disorders : official journal of the Movement Disorder Society.
[139] W. Yao,et al. Dopaminergic signaling in dendritic spines. , 2008, Biochemical pharmacology.
[140] D. Firsov,et al. Molecular cloning of two rat GRK6 splice variants. , 1997, The American journal of physiology.
[141] G. Gerhardt,et al. Striatal Glutamate Release in l-DOPA-Induced Dyskinetic Animals , 2013, PloS one.
[142] E. Snyder,et al. Neuroprotection through Delivery of Glial Cell Line-Derived Neurotrophic Factor by Neural Stem Cells in a Mouse Model of Parkinson's Disease , 2001, The Journal of Neuroscience.
[143] A. Bastian. Learning to predict the future: the cerebellum adapts feedforward movement control , 2006, Current Opinion in Neurobiology.
[144] M. Morelli,et al. Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression , 2010, Experimental Neurology.
[145] A. Björklund,et al. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. , 2005, Brain : a journal of neurology.
[146] A. Benabid,et al. De novo and long-term l-Dopa induce both common and distinct striatal gene profiles in the hemiparkinsonian rat , 2009, Neurobiology of Disease.
[147] Ji-Kyung Choi,et al. In vivo evidence of D3 dopamine receptor sensitization in parkinsonian primates and rodents with l-DOPA-induced dyskinesias , 2007, Neurobiology of Disease.
[148] A. Benabid,et al. Deep brain stimulation , 2004, Cell and Tissue Research.
[149] J. Langston,et al. Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the squirrel monkey , 2002, Neuroscience.
[150] D. Sulzer,et al. Presynaptic effects of levodopa and their possible role in dyskinesia , 2015, Movement disorders : official journal of the Movement Disorder Society.
[151] P. Seeman. Brain dopamine receptors. , 1980, Pharmacological reviews.
[152] A. Lang,et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease , 2006, Neurology.
[153] Thomas Boraud,et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function , 2003, Nature Medicine.
[154] V. Gurevich,et al. The Nature of the Arrestin·Receptor Complex Determines the Ultimate Fate of the Internalized Receptor* , 2003, The Journal of Biological Chemistry.
[155] S. A. O. Lim,et al. Enhanced striatal cholinergic neuronal activity mediates l-DOPA–induced dyskinesia in parkinsonian mice , 2010, Proceedings of the National Academy of Sciences.
[156] J. Violin,et al. β-Arrestin-biased ligands at seven-transmembrane receptors , 2007 .
[157] G. Arbuthnott,et al. Spine density on neostriatal neurones changes with 6-hydroxydopamine lesions and with age , 1989, Brain Research.
[158] M. Caron,et al. beta-Arrestin: a protein that regulates beta-adrenergic receptor function. , 1990, Science.
[159] V. V. Gurevich,et al. l-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain , 2005, Neurobiology of Disease.
[160] I. Melnikova,et al. Targeting protein kinases , 2004, Nature Reviews Drug Discovery.
[161] S. Iversen,et al. Characterisation of dyskinesias induced byl-dopa in MPTP-treated squirrel monkeys , 2005, Psychopharmacology.
[162] Paul Greengard,et al. Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors , 2010, Proceedings of the National Academy of Sciences.
[163] P. Stanzione,et al. Two‐year, randomized, controlled study of safinamide as add‐on to levodopa in mid to late Parkinson's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.
[164] Qin Li,et al. RGS9–2 Negatively Modulates l-3,4-Dihydroxyphenylalanine-Induced Dyskinesia in Experimental Parkinson's Disease , 2007, The Journal of Neuroscience.
[165] C. Marsden,et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset , 1984, Neuroscience Letters.
[166] P. Greengard,et al. Resource Application of a Translational Profiling Approach for the Comparative Analysis of CNS Cell Types , 2009 .
[167] Nikolaus R. McFarland,et al. Striatonigrostriatal Pathways in Primates Form an Ascending Spiral from the Shell to the Dorsolateral Striatum , 2000, The Journal of Neuroscience.
[168] P. Bédard,et al. Primate Models of Parkinson’s Disease , 1992 .
[169] L. Golbe. Young‐onset Parkinson's disease , 1991, Neurology.
[170] T. Chase,et al. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD , 2005, Experimental Neurology.
[171] L. Tremblay,et al. Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism , 1991, Brain Research.
[172] J. Lindstrom,et al. Long-Term Nicotine Treatment Decreases Striatal α6* Nicotinic Acetylcholine Receptor Sites and Function in Mice , 2005, Molecular Pharmacology.
[173] M. Savasta,et al. Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson’s disease , 2013, Molecular Psychiatry.
[174] Charles J. Wilson,et al. Cholinergic interneuron characteristics and nicotinic properties in the striatum. , 2002, Journal of neurobiology.
[175] M. Leibowitz,et al. Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease , 1975, Neurology.
[176] F. Menniti,et al. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease , 2004, Experimental Neurology.
[177] E. Bézard,et al. Subthalamic stimulation elicits hemiballismus in normal monkey , 1997, Neuroreport.
[178] J. Dostrovsky,et al. Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine. , 2000, Annals of neurology.
[179] P. Jenner,et al. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L‐dopa in the MPTP‐treated marmoset , 1998, Movement disorders : official journal of the Movement Disorder Society.
[180] W. Tischmeyer,et al. Activation of immediate early genes and memory formation , 1999, Cellular and Molecular Life Sciences CMLS.
[181] R. Andrade,et al. Molecular characterization of human and rat RGS 9L, a novel splice variant enriched in dopamine target regions, and chromosomal localization of the RGS 9 gene. , 1998, Molecular pharmacology.
[182] D. Jacobowitz,et al. Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey. , 1984, Psychopharmacology bulletin.
[183] Qin Li,et al. Lentiviral Overexpression of GRK6 Alleviates l-Dopa–Induced Dyskinesia in Experimental Parkinson’s Disease , 2010, Science Translational Medicine.
[184] Serge H. Ahmed,et al. A Choice‐Based Screening Method for Compulsive Drug Users in Rats , 2013, Current protocols in neuroscience.
[185] E. Hirsch,et al. Blood vessels change in the mesencephalon of patients with Parkinson's disease , 1999, The Lancet.
[186] P. Cortelli,et al. Pharmacodynamic modeling of oral levodopa , 1993, Neurology.
[187] A. Lees,et al. Low dose quetiapine for drug induced dyskinesias in Parkinson’s disease: a double blind cross over study , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[188] H. Walter,et al. When benefitting a patient increases the risk for harm for third persons - the case of treating pedophilic Parkinsonian patients with deep brain stimulation. , 2014, International journal of law and psychiatry.
[189] J. Brotchie,et al. Effect of histamine H2 receptor antagonism on levodopa–induced dyskinesia in the MPTP‐macaque model of Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[190] Marc Parmentier,et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor , 1995, Nature.
[191] T. Napier,et al. Pramipexole- and methamphetamine-induced reward-mediated behavior in a rodent model of Parkinson's disease and controls , 2012, Behavioural Brain Research.
[192] J. Langston,et al. Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) , 1985, Neurology.
[193] O. Hornykiewicz,et al. Der L-Dioxyphenylalanin (=L-DOPA)-Effekt beim Parkinson-Syndrom des Menschen: Zur Pathogenese und Behandlung der Parkinson-Akinese , 2004, Archiv für Psychiatrie und Nervenkrankheiten.
[194] E. Bézard,et al. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease , 2005, Neuropharmacology.
[195] Daniel S. McGehee,et al. Striatal cholinergic interneuron regulation and circuit effects , 2014, Front. Synaptic Neurosci..
[196] P. Greengard,et al. Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia , 2014, Proceedings of the National Academy of Sciences.
[197] J. Changeux,et al. Nicotine enhances intracellular nicotinic receptor maturation: A novel mechanism of neural plasticity? , 2006, Journal of Physiology-Paris.
[198] P. Sokoloff,et al. Coexpression of dopamine D1 and D3 receptors in islands of Calleja and shell of nucleus accumbens of the rat: opposite and synergistic functional interactions , 1998, The European journal of neuroscience.
[199] J. Brotchie,et al. The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.
[200] H. Matthes,et al. Distribution of nociceptin/orphanin FQ receptor transcript in human central nervous system and immune cells , 1998, Journal of Neuroimmunology.
[201] J. Powell,et al. Efferent synaptic connections of grafted dopaminergic neurons reinnervating the host neostriatum: a tyrosine hydroxylase immunocytochemical study , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[202] F. Monsma,et al. Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[203] E. Bézard,et al. Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[204] S. Duty,et al. Brain Morphometry and the Neurobiology of Levodopa-Induced Dyskinesias: Current Knowledge and Future Potential for Translational Pre-Clinical Neuroimaging Studies , 2014, Front. Neurol..
[205] P. Tuite,et al. Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005) , 2008, Annals of neurology.
[206] C. Gotti,et al. Subunit Composition of Nicotinic Receptors in Monkey Striatum: Effect of Treatments with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine or l-DOPA , 2005, Molecular Pharmacology.
[207] Xuechu Zhen,et al. Activation of Extracellular Signal-Regulated Protein Kinases Is Associated with a Sensitized Locomotor Response to D2Dopamine Receptor Stimulation in Unilateral 6-Hydroxydopamine-Lesioned Rats , 2000, The Journal of Neuroscience.
[208] J. P. Huston,et al. UNILATERAL 6-HYDROXYDOPAMINE LESIONS OF MESO-STRIATAL DOPAMINE NEURONS AND THEIR PHYSIOLOGICAL SEQUELAE , 1996, Progress in Neurobiology.
[209] Abdelhamid Benazzouz,et al. Noradrenaline and Parkinson's Disease , 2011, Front. Syst. Neurosci..
[210] Anatol C. Kreitzer,et al. Striatal Plasticity and Basal Ganglia Circuit Function , 2008, Neuron.
[211] L. Grégoire,et al. Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias , 2010, Neuroscience.
[212] P. Bédard,et al. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. , 1993, Clinical neuropharmacology.
[213] R. Gainetdinov,et al. Muscarinic Supersensitivity and Impaired Receptor Desensitization in G Protein–Coupled Receptor Kinase 5–Deficient Mice , 1999, Neuron.
[214] G. Engberg. A metabolite of buspirone increases locus coeruleus activity via alpha2-receptor blockade , 2005, Journal of Neural Transmission.
[215] B. Neustadt,et al. Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of Movement Disorders and Depression , 2009, Journal of Pharmacology and Experimental Therapeutics.
[216] M. Cenci,et al. Ratings of L‐DOPA‐Induced Dyskinesia in the Unilateral 6‐OHDA Lesion Model of Parkinson's Disease in Rats and Mice , 2007, Current protocols in neuroscience.
[217] M. Andersson,et al. Alterations in Cortical and Basal Ganglia Levels of Opioid Receptor Binding in a Rat Model of l -DOPA-Induced Dyskinesia , 2001, Neurobiology of Disease.
[218] Susan H Fox,et al. Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson’s disease , 2003, Experimental Neurology.
[219] E. Gurevich,et al. Sex differences in the activity of signalling pathways and expression of G-protein-coupled receptor kinases in the neonatal ventral hippocampal lesion model of schizophrenia. , 2011, The international journal of neuropsychopharmacology.
[220] G. Linazasoro. Anticholinergics and dyskinesia. , 1994, Movement disorders : official journal of the Movement Disorder Society.
[221] N. Mercuri,et al. Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates l-DOPA-induced dyskinesia in dopamine-denervated mice , 2014, Experimental Neurology.
[222] Eduardo E. Benarroch,et al. Locus coeruleus , 2017, Cell and Tissue Research.
[223] A. Lees,et al. Anticholinergics for symptomatic management of Parkinson's disease. , 2002, The Cochrane database of systematic reviews.
[224] R. Lefkowitz,et al. Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[225] P. Calabresi,et al. Unilateral dopamine denervation blocks corticostriatal LTP. , 1999, Journal of neurophysiology.
[226] R. Katzenschlager,et al. Punding and dyskinesias , 2006, Movement disorders : official journal of the Movement Disorder Society.
[227] C. Adler,et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. , 1998, Archives of neurology.
[228] J. D. Parkes,et al. Fluctuations of disability in Parkinson's disease – clinical aspects , 1981 .
[229] Paul Greengard,et al. DARPP-32: Regulator of the Efficacy of Dopaminergic Neurotransmission , 1998 .
[230] J. Girault,et al. Gene Expression Analyses Identify Narp Contribution in the Development of l-DOPA-Induced Dyskinesia , 2015, The Journal of Neuroscience.
[231] A. Lang,et al. Punding prevalence in Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.
[232] D. Charvin,et al. A novel series of metabotropic glutamate receptor 5 negative allosteric modulators based on a 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine core. , 2013, Bioorganic & medicinal chemistry letters.
[233] P. Blier,et al. Autoregulation of serotonin neurons: role in antidepressant drug action. , 1999, Pharmacological reviews.
[234] J M Willets,et al. Selective Reduction in A2 Adenosine Receptor Desensitization Following Antisense‐Induced Suppression of G Protein‐Coupled Receptor Kinase 2 Expression , 1999, Journal of neurochemistry.
[235] E. Bézard,et al. Experimental Models of Parkinson's Disease: From the Static to the Dynamic , 1998, Reviews in the neurosciences.
[236] C. Clarke,et al. A Randomized, Double-blind, Placebo-controlled, Ascending-dose Tolerability and Safety Study of Remacemide as Adjuvant Therapy in Parkinson's Disease with Response Fluctuations , 2001, Clinical neuropharmacology.
[237] Qin Li,et al. A critique of available scales and presentation of the non‐human primate dyskinesia rating scale , 2012, Movement disorders : official journal of the Movement Disorder Society.
[238] G. Rylander. Psychoses and the punding and choreiform syndromes in addiction to central stimulant drugs. , 1972, Psychiatria, neurologia, neurochirurgia.
[239] J. C. Stoof,et al. Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum , 1981, Nature.
[240] D. Choquet,et al. NMDA receptor surface mobility depends on NR2A-2B subunits , 2006, Proceedings of the National Academy of Sciences.
[241] Kuei Yuan Tseng,et al. Aberrant Restoration of Spines and their Synapses in l-DOPA-Induced Dyskinesia: Involvement of Corticostriatal but Not Thalamostriatal Synapses , 2013, The Journal of Neuroscience.
[242] A. Björklund,et al. The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study , 2015, Neurobiology of Aging.
[243] R. Franco,et al. l-DOPA disrupts adenosine A2A–cannabinoid CB1–dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies , 2014, Experimental Neurology.
[244] T. Di Paolo,et al. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy. , 1997, Brain research. Molecular brain research.
[245] J. Labandeira-Garcia,et al. Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1β , 2014, Experimental Neurology.
[246] J. Langston,et al. The selective κ-opioid receptor agonist U50,488 reduces l-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates , 2007, Experimental Neurology.
[247] J. Dostrovsky,et al. Lack of depotentiation at basal ganglia output neurons in PD patients with levodopa-induced dyskinesia , 2014, Neurobiology of Disease.
[248] P. Stanzione,et al. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations , 2013, Movement disorders : official journal of the Movement Disorder Society.
[249] Erwan Bezard,et al. Phenotype of Striatofugal Medium Spiny Neurons in Parkinsonian and Dyskinetic Nonhuman Primates: A Call for a Reappraisal of the Functional Organization of the Basal Ganglia , 2006, The Journal of Neuroscience.
[250] P. Danielson,et al. Embryonic mesencephalic grafts increase levodopa‐induced forelimb hyperkinesia in parkinsonian rats , 2003, Movement disorders : official journal of the Movement Disorder Society.
[251] N. Mercuri,et al. Blockade of Nociceptin/orphanin Fq Receptor Signaling in Rat Substantia Nigra Pars Reticulata Stimulates Nigrostriatal Dopaminergic Transmission and Motor Behavior ,lys 15 ]n/ofq(1–13)-nh 2 ) (a Selective Nop Receptor Peptide Antagonist) Stimulated It. N/ofq Microinjected in the Sub- Stantia Nigra P , 2022 .
[252] Arnaud H. Muller,et al. Central and peripheral endogenous morphine , 2009 .
[253] D B Calne,et al. Compensatory mechanisms in degenerative neurologic diseases. Insights from parkinsonism. , 1991, Archives of neurology.
[254] P. Andrén,et al. Altered extracellular striatal in vivo biotransformation of the opioid neuropeptide dynorphin A(1-17) in the unilateral 6-OHDA rat model of Parkinson's disease. , 2005, Journal of mass spectrometry : JMS.
[255] G. Fénelon,et al. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. , 2000, Brain : a journal of neurology.
[256] P. Brundin,et al. Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats , 2009, Experimental Neurology.
[257] J. Brotchie,et al. μ- and δ-Opioid Receptor Antagonists Reduce Levodopa-Induced Dyskinesia in the MPTP-Lesioned Primate Model of Parkinson's Disease , 2001, Experimental Neurology.
[258] P. Calabresi,et al. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation , 2008, Neurobiology of Disease.
[259] Dinesh Kumar,et al. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. , 2004, British journal of clinical pharmacology.
[260] T. Suda,et al. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. , 1999, Neuroreport.
[261] F. Pedata,et al. Modification of adenosine extracellular levels and adenosine A(2A) receptor mRNA by dopamine denervation. , 2002, European journal of pharmacology.
[262] M. Besson,et al. Involvement of the Extracellular Signal-Regulated Kinase Cascade for Cocaine-Rewarding Properties , 2000, The Journal of Neuroscience.
[263] R. Hauser,et al. Double‐blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.
[264] M. Fälth,et al. l-DOPA-induced Dyskinesia is Associated with Regional Increase of Striatal Dynorphin Peptides as Elucidated by Imaging Mass Spectrometry , 2011, Molecular & Cellular Proteomics.
[265] K. E Bridge,et al. Autoradiographic localization of 125i[tyr14] nociceptin/orphanin fq binding sites in macaque primate cns , 2003, Neuroscience.
[266] P. Calabresi,et al. Derangement of Ras-Guanine Nucleotide-Releasing Factor 1 (Ras-GRF1) and Extracellular Signal-Regulated Kinase (ERK) Dependent Striatal Plasticity in L-DOPA-Induced Dyskinesia , 2015, Biological Psychiatry.
[267] P. Frankland,et al. Uncoupling the D1-N-Methyl-D-Aspartate (NMDA) Receptor Complex Promotes NMDA-Dependent Long-Term Potentiation and Working Memory , 2010, Biological Psychiatry.
[268] B. Långström,et al. Levodopa‐induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET , 1996, Neurology.
[269] Y. Goshima,et al. l-DOPA systems for blood pressure regulation in the lower brainstem , 1995, Neuroscience Research.
[270] John R. Adams,et al. Parkinson's disease: in vivo assessment of disease progression using positron emission tomography. , 2005, Brain research. Molecular brain research.
[271] R. Hen,et al. G(olf)alpha mediates dopamine D1 receptor signaling. , 2000, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[272] E. Shiorring. Psychopathology induced by 'speed' drugs - (amphetamine, cocaine and related compounds) , 1980 .
[273] D Oakes,et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease , 2003, Experimental Neurology.
[274] Maxime Dahan,et al. Transient directed motions of GABA(A) receptors in growth cones detected by a speed correlation index. , 2007, Biophysical journal.
[275] J. Parkinson. An Essay on the Shaking Palsy , 2002 .
[276] L. Grégoire,et al. AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys. , 2014, Parkinsonism & related disorders.
[277] S. R. Nash,et al. Differential Regulation of Dopamine D1A Receptor Responsiveness by Various G Protein-coupled Receptor Kinases (*) , 1996, The Journal of Biological Chemistry.
[278] Antonio Cerasa,et al. A network centred on the inferior frontal cortex is critically involved in levodopa-induced dyskinesias. , 2015, Brain : a journal of neurology.
[279] K. Shannon,et al. Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats , 2006, Neurobiology of Disease.
[280] Suzanne N Haber,et al. Dopamine Replacement Therapy Does Not Restore the Full Spectrum of Normal Pallidal Activity in the 1-Methyl-4-Phenyl-1,2,3,6-Tetra-Hydropyridine Primate Model of Parkinsonism , 2006, The Journal of Neuroscience.
[281] Marios Politis,et al. Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson’s Patients with Neural Transplants , 2010, Science Translational Medicine.
[282] O. Hornykiewicz,et al. Functional sensitization of striatal dopamine D1 receptors in the 6-hydroxydopamine-lesioned rat , 1992, Brain Research.
[283] O. Blin,et al. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease , 1994, Movement disorders : official journal of the Movement Disorder Society.
[284] P. Seeman,et al. Low density of dopamine D4 receptors in Parkinson's, schizophrenia, and control brain striata , 1993, Synapse.
[285] M Schulzer,et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. , 2001, Annals of neurology.
[286] P. Brown,et al. Beta band stability over time correlates with Parkinsonian rigidity and bradykinesia , 2012, Experimental Neurology.
[287] P. D. Blasi,et al. Repetitive transcranial magnetic stimulation transiently reduces punding in Parkinson’s disease: a preliminary study , 2013, Journal of Neural Transmission.
[288] G. Nikkhah,et al. Extent of pre-operative L-DOPA-induced dyskinesia predicts the severity of graft-induced dyskinesia after fetal dopamine cell transplantation , 2011, Experimental Neurology.
[289] M. Davie. Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma. , 2007, The Journal of neuropsychiatry and clinical neurosciences.
[290] J. Welge,et al. Genotype and smoking history affect risk of levodopa‐induced dyskinesias in Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.
[291] G Vassart,et al. ORL1, a novel member of the opioid receptor family , 1994, FEBS letters.
[292] Effects of pramipexole on the reinforcing effectiveness of stimuli that were previously paired with cocaine reinforcement in rats , 2011, Psychopharmacology.
[293] Erwan Bezard,et al. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders , 2009, The Lancet Neurology.
[294] P. Jenner,et al. Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets , 2002, Neuroscience.
[295] E. Nestler,et al. Elevated levels of DeltaFosB and RGS9 in striatum in Parkinson's disease. , 2001, Biological psychiatry.
[296] Andrew J Lees,et al. Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series , 2007, Movement disorders : official journal of the Movement Disorder Society.
[297] T. Sotnikova,et al. The role of GRK6 in animal models of Parkinson's Disease and L-DOPA treatment , 2012, Scientific Reports.
[298] T. Shippenberg,et al. Differential involvement of D1 and D2 dopamine receptors in the expression of morphine withdrawal signs in rats. , 1996, Behavioural pharmacology.
[299] P. Derambure,et al. Effect of dopaminergic substances on sleep/wakefulness in saline‐ and MPTP‐treated mice , 2008, Journal of sleep research.
[300] A. Benazzouz,et al. MPTP induced hemiparkinsonism in monkeys: behavioral, mechanographic, electromyographic and immunohistochemical studies , 2004, Experimental Brain Research.
[301] E. Tolosa,et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial , 2007, The Lancet Neurology.
[302] S. Baader,et al. Dynamics of beta2-adrenergic receptor-ligand complexes on living cells. , 2004, Biochemistry.
[303] Werner Poewe,et al. Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004 , 2005, Movement disorders : official journal of the Movement Disorder Society.
[304] K. Steece-Collier,et al. Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in parkinsonian rats , 2009, The Journal of comparative neurology.
[305] M. Mimura,et al. Effects of zonisamide on tardive dyskinesia: A preliminary open-label trial , 2012, Journal of the Neurological Sciences.
[306] J. Joyce. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine I. Effects of intranigral or intracerebroventricular 6-hydroxydopamine lesions of the mesostriatal dopamine system , 1991, Experimental Neurology.
[307] B. Bioulac,et al. Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease , 2011, Neurobiology of Disease.
[308] S. Konitsiotis,et al. Levetiracetam for the management of levodopa‐induced dyskinesias in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[309] G. Meco,et al. Buspirone in levodopa-induced dyskinesias. , 1994, Clinical neuropharmacology.
[310] ChristopheGuignabert,et al. Serotonin Transporter Inhibition Prevents and Reverses Monocrotaline-Induced Pulmonary Hypertension in Rats , 2005 .
[311] P. Fischer,et al. The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases. , 2004, Current medicinal chemistry.
[312] M. Geffard,et al. Baroreceptor-aortic nerve-mediated release of endogenous L-3,4-dihydroxyphenylalanine and its tonic depressor function in the nucleus tractus solitarii of rats , 1994, Neuroscience.
[313] J. Woods,et al. Drug and Reinforcement History as Determinants of the Response-Maintaining Effects of Quinpirole in the Rat , 2007, Journal of Pharmacology and Experimental Therapeutics.
[314] Qin Li,et al. Permeability of blood–brain barrier in macaque model of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced Parkinson disease , 2016, Synapse.
[315] G. Deuschl,et al. A randomized trial of deep-brain stimulation for Parkinson's disease. , 2006, The New England journal of medicine.
[316] D. Riche,et al. Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in parkinson's disease , 1994, Neuroscience.
[317] Hideki Oshima,et al. Direct Effect of Subthalamic Nucleus Stimulation on Levodopa-Induced Peak-Dose Dyskinesia in Patients with Parkinson’s Disease , 2006, Stereotactic and Functional Neurosurgery.
[318] T. Dalkara,et al. Compartmental changes in expression of c-Fos and FosB proteins in intact and dopamine-depleted striatum after chronic apomorphine treatment , 1999, Brain Research.
[319] B. Cox,et al. Alterations of N/OFQ and NOP receptor gene expression in the substantia nigra and caudate putamen of MPP+ and 6-OHDA lesioned rats , 2009, Neuropharmacology.
[320] A. Quattrone,et al. Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. , 1999, Neurology.
[321] Erwan Bezard,et al. Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies , 2001, Nature Reviews Neuroscience.
[322] Ji-Kyung Choi,et al. Brain hemodynamic changes mediated by dopamine receptors: Role of the cerebral microvasculature in dopamine-mediated neurovascular coupling , 2006, NeuroImage.
[323] H. Koh,et al. Positive association between striatal serotonin level and abnormal involuntary movements in chronic l-DOPA-treated hemiparkinsonian rats , 2011, Brain Research Bulletin.
[324] E. Bézard,et al. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracelullar striatal dopamine , 2006, Neurobiology of Disease.
[325] A. Destée,et al. Withdrawing amantadine in dyskinetic patients with Parkinson disease , 2014, Neurology.
[326] M. Cenci,et al. The “motor complication syndrome” in rats with 6-OHDA lesions treated chronically with l-DOPA: Relation to dose and route of administration , 2007, Behavioural Brain Research.
[327] R. Mach,et al. Evaluation of D2 and D3 dopamine receptor selective compounds on l-dopa-dependent abnormal involuntary movements in rats , 2009, Neuropharmacology.
[328] H. Akil,et al. Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: An in situ hybridization study , 1994, The Journal of comparative neurology.
[329] H. Putter,et al. Risk factors for hallucinations in Parkinson's disease: Results from a large prospective cohort study , 2013, Movement disorders : official journal of the Movement Disorder Society.
[330] Daniel Choquet,et al. Direct imaging of lateral movements of AMPA receptors inside synapses , 2003, The EMBO journal.
[331] P. Salin,et al. Forelimb dyskinesia mediated by high‐frequency stimulation of the subthalamic nucleus is linked to rapid activation of the NR2B subunit of N‐methyl‐d‐aspartate receptors , 2010, The European journal of neuroscience.
[332] Riccardo Viaro,et al. Nociceptin/Orphanin FQ Modulates Motor Behavior and Primary Motor Cortex Output Through Receptors Located in Substantia Nigra Reticulata , 2009, Neuropsychopharmacology.
[333] P. Brodal,et al. The projection from the nucleus reticularis tegmenti pontis to the cerebellum in the rhesus monkey , 2004, Experimental Brain Research.
[334] Vesna Sossi,et al. Changes of Dopamine Turnover in the Progression of Parkinson's Disease as Measured by Positron Emission Tomography: Their Relation to Disease-Compensatory Mechanisms , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[335] U. Bonuccelli,et al. Serotonergic antidepressant drugs and L‐dopa‐induced dyskinesias in Parkinson's disease , 2015, Acta neurologica Scandinavica.
[336] Niall P Quinn,et al. Reckless generosity in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[337] W. Hall,et al. Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field. , 2011, Addiction.
[338] Simon Hong,et al. The Globus Pallidus Sends Reward-Related Signals to the Lateral Habenula , 2008, Neuron.
[339] I. Mitchell,et al. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. , 1992, Brain : a journal of neurology.
[340] A. Björklund,et al. Dyskinesias following neural transplantation in Parkinson's disease , 2002, Nature Neuroscience.
[341] M. Trimble,et al. The Lateral Habenula: No Longer Neglected , 2008, CNS Spectrums.
[342] M. Cenci. L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment. , 2007, Parkinsonism & related disorders.
[343] Y. Wong,et al. The ORL1 Receptor: Molecular Pharmacology and Signalling Mechanisms , 2002, Neurosignals.
[344] L. Tremblay,et al. A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery. , 2007, Brain : a journal of neurology.
[345] F. Grandas,et al. Risk factors for levodopa-induced dyskinesias in Parkinson’s disease , 1999, Journal of Neurology.
[346] F. Turkheimer,et al. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. , 2014, The Journal of clinical investigation.
[347] Mark Hallett,et al. Impulsive choice and response in dopamine agonist-related impulse control behaviors , 2009, Psychopharmacology.
[348] G. Di Chiara,et al. Changes in the D1 receptor-adenylate cyclase complex after priming. , 1990, European journal of pharmacology.
[349] P. Calabresi,et al. Pathological synaptic plasticity in the striatum: implications for Parkinson's disease. , 2005, Neurotoxicology.
[350] A. Björklund,et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. , 2008, Brain : a journal of neurology.
[351] E. Albuquerque,et al. Mammalian nicotinic acetylcholine receptors: from structure to function. , 2009, Physiological reviews.
[352] Robert J. Lefkowitz,et al. Transduction of Receptor Signals by ß-Arrestins , 2005, Science.
[353] R. Depoortère,et al. NLX-112, a novel 5-HT1A receptor agonist for the treatment of l-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat , 2015, Experimental Neurology.
[354] Erwan Bezard,et al. Involvement of Sensorimotor, Limbic, and Associative Basal Ganglia Domains in L-3,4-Dihydroxyphenylalanine-Induced Dyskinesia , 2005, The Journal of Neuroscience.
[355] A. Stoessl. Central pharmacokinetics of levodopa: Lessons from imaging studies , 2015, Movement disorders : official journal of the Movement Disorder Society.
[356] A. Lang,et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. , 2007, Archives of neurology.
[357] Duvoisin Rc. Variations in the "on-off" phenomenon. , 1974 .
[358] M. Merello,et al. Apomorphine induces changes in GPi spontaneous outflow in patients with parkinson's disease , 1999, Movement disorders : official journal of the Movement Disorder Society.
[359] J. P. Huston,et al. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments , 1996, Progress in Neurobiology.
[360] J. Benovic,et al. Arrestins and two receptor kinases are upregulated in Parkinson's disease with dementia , 2008, Neurobiology of Aging.
[361] P. Brodal,et al. The pontocerebellar projection in the rhesus monkey: An experimental study with retrograde axonal transport of horseradish peroxidase , 1979, Neuroscience.
[362] E. Bézard,et al. D1 dopamine receptor stimulation impairs striatal proteasome activity in Parkinsonism through 26S proteasome disassembly , 2015, Neurobiology of Disease.
[363] G. Deuschl,et al. Surgical treatment of Parkinson's disease. , 1999, Current opinion in neurology.
[364] P. Calabresi,et al. Long-term synaptic depression in the striatum: physiological and pharmacological characterization , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[365] A. Aristieta,et al. The locus coeruleus Is Directly Implicated in L-DOPA-Induced Dyskinesia in Parkinsonian Rats: An Electrophysiological and Behavioural Study , 2011, PloS one.
[366] M. Cenci,et al. Investigating the molecular mechanisms of L-DOPA-induced dyskinesia in the mouse. , 2014, Parkinsonism & related disorders.
[367] M. Morari,et al. RAPID COMMUNICATION: Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol‐induced akinesia and normalizes nigral glutamate release , 2004, Journal of neurochemistry.
[368] W. Hall,et al. Compulsive use of dopamine replacement therapy: a model for stimulant drug addiction? , 2012, Addiction.
[369] A. Lang,et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. , 2010, Archives of neurology.
[370] D. Eidelberg,et al. Effects of levodopa on regional cerebral metabolism and blood flow , 2015, Movement disorders : official journal of the Movement Disorder Society.
[371] J. Liebman,et al. Effects of dopamine agonists, catecholamine depletors, and cholinergic and GABAergic drugs on acute dyskinesias in squirrel monkeys , 1983, Psychopharmacology.
[372] O. Hornykiewicz,et al. Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa‐induced motor complications , 2003, Movement disorders : official journal of the Movement Disorder Society.
[373] P. Deyn,et al. Effect and safety of duodenal levodopa infusion in advanced Parkinson’s disease: a retrospective multicenter outcome assessment in patient routine care , 2013, Journal of Neural Transmission.
[374] M. Millan,et al. Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats. , 1997, Journal of neurochemistry.
[375] R. Hauser,et al. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients , 2016, The International journal of neuroscience.
[376] A. Destée,et al. AFQ056 in Parkinson patients with levodopa‐induced dyskinesia: 13‐week, randomized, dose‐finding study , 2013, Movement disorders : official journal of the Movement Disorder Society.
[377] P. Ravenscroft,et al. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia , 2013, Experimental Neurology.
[378] J. Yamada,et al. Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia , 2014, Neurobiology of Disease.
[379] R. Moratalla,et al. Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3−/− aphakia mice , 2015, Neurobiology of Disease.
[380] A. J. Stoessl,et al. Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations , 2000, Journal of Neural Transmission.
[381] G. Di Chiara,et al. Time and dose dependence of the 'priming' of the expression of dopamine receptor supersensitivity. , 1989, European journal of pharmacology.
[382] M. Mellone,et al. Modulation of NMDA receptor at the synapse: promising therapeutic interventions in disorders of the nervous system. , 2013, European journal of pharmacology.
[383] Qin Li,et al. Altered D1 dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates , 2007, Neurobiology of Disease.
[384] J. Salamone,et al. Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism. , 2008, Frontiers in bioscience : a journal and virtual library.
[385] E. Tronci,et al. Role of Serotonin Neurons in L-DOPA- and Graft-Induced Dyskinesia in a Rat Model of Parkinson's Disease , 2012, Parkinson's disease.
[386] S. Salvadori,et al. Blockade of Nociceptin/Orphanin FQ Transmission Attenuates Symptoms and Neurodegeneration Associated with Parkinson's Disease , 2005, The Journal of Neuroscience.
[387] H. Ehringer,et al. Verteilung Von Noradrenalin Und Dopamin (3-Hydroxytyramin) Im Gehirn Des Menschen Und Ihr Verhalten Bei Erkrankungen Des Extrapyramidalen Systems , 2005, Klinische Wochenschrift.
[388] M. Trulson,et al. Dopamine neuron transplants: electrophysiological unit activity of intrastriatal nigral grafts in freely moving cats. , 1987, Life sciences.
[389] L. Wilkins. Zonisamide improves motor function in Parkinson disease: A randomized, double-blind study , 2007, Neurology.
[390] A. Benabid,et al. Coordinated and Spatial Upregulation of Arc in Striatonigral Neurons Correlates With L-Dopa-Induced Behavioral Sensitization in Dyskinetic Rats , 2005, Journal of neuropathology and experimental neurology.
[391] T. Chase,et al. Dietary influences on the antiparkinsonian response to levodopa. , 1987, Archives of neurology.
[392] B. Bioulac,et al. MPTP primate model of Parkinson's disease: a mechanographic and electromyographic study , 1985, Brain Research.
[393] M. Millan,et al. Actions at sites other than D3 receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats , 2006, Experimental Neurology.
[394] J. Nutt,et al. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. , 2002, Archives of neurology.
[395] T. Lamb,et al. The Gain of Rod Phototransduction Reconciliation of Biochemical and Electrophysiological Measurements , 2000, Neuron.
[396] A. Björklund,et al. Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. , 2008, Progress in brain research.
[397] T. Svensson,et al. Deuterium substitutions in the L-DOPA molecule improve its anti-akinetic potency without increasing dyskinesias , 2010, Experimental Neurology.
[398] M. Morelli,et al. Selective modifications in GAD67 mRNA levels in striatonigral and striatopallidal pathways correlate to dopamine agonist priming in 6‐hydroxydopamine‐lesioned rats , 2003, The European journal of neuroscience.
[399] L. Descarries,et al. Maladaptive plasticity of serotonin axon terminals in levodopa‐induced dyskinesia , 2010, Annals of neurology.
[400] C. Barnum,et al. Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat , 2008, Neuropharmacology.
[401] M. Hallett,et al. Dopamine agonists and risk: impulse control disorders in Parkinson's disease. , 2011, Brain : a journal of neurology.
[402] A. Grace,et al. Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment , 2010, Movement disorders : official journal of the Movement Disorder Society.
[403] M. Besson,et al. Cortical and nigral deafferentation and striatal cholinergic markers in the rat dorsal striatum: different effects on the expression of mRNAs encoding choline acetyltransferase and muscarinic m1 and m4 receptors , 1999, The European journal of neuroscience.
[404] P. Braga-Neto,et al. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. , 2005, Parkinsonism & related disorders.
[405] G. Pozzessere,et al. Low dosage clozapine effects on L‐dopa induced dyskinesias in parkinsonian patients , 1998, Acta neurologica Scandinavica.
[406] J. Matsumoto,et al. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. , 2005, Parkinsonism & related disorders.
[407] J. Tepper,et al. Electrophysiological characteristics of cells within mesencephalon suspension grafts , 1991, Neuroscience.
[408] D. Kirik,et al. Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA–induced dyskinesia in rats , 2010, Proceedings of the National Academy of Sciences.
[409] J M Smith,et al. Compulsive buying: a report of 20 cases. , 1994, The Journal of clinical psychiatry.
[410] Paola Piccini,et al. Priorities in Parkinson's disease research , 2011, Nature Reviews Drug Discovery.
[411] Famotidine, a Histamine H2 Receptor Antagonist, Does Not Reduce Levodopa‐Induced Dyskinesia in Parkinson's Disease: A Proof‐of‐Concept Study , 2014, Movement disorders clinical practice.
[412] C. Missale,et al. Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease , 2013, Neurobiology of Disease.
[413] P. Gubellini,et al. Synergy between l-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: Implications for Parkinson's disease treatment and dyskinesia , 2013, Neuropharmacology.
[414] Andrew J Lees,et al. Excessive hoarding in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[415] Mark Stacy,et al. Clinical spectrum of impulse control disorders in Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.
[416] E. Bézard,et al. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. , 2005, Parkinsonism & related disorders.
[417] P. Blanchet,et al. Short-term effects of high-dose 17β-estradiol in postmenopausal PD patients , 1999, Neurology.
[418] Thomas H. McNeill,et al. Atrophy of medium spiny I striatal dendrites in advanced Parkinson's disease , 1988, Brain Research.
[419] Tejas Sankar,et al. Magnetic resonance imaging and deep brain stimulation. , 2011, Journal of neurosurgery.
[420] D. Mash,et al. Dopamine D(1) receptor expression in human basal ganglia and changes in Parkinson's disease. , 2001, Brain research. Molecular brain research.
[421] L. Seeberger,et al. A randomized, controlled trial of remacemide for motor fluctuations in Parkinson’s disease , 2001, Neurology.
[422] H. Kennedy,et al. Early Presymptomatic and Long-Term Changes of Rest Activity Cycles and Cognitive Behavior in a MPTP-Monkey Model of Parkinson's Disease , 2011, PloS one.
[423] L. Defebvre,et al. Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[424] I. Mitchell,et al. Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus , 1985, Neuroscience Letters.
[425] L. Tremblay,et al. Behavioral Recovery in MPTP-Treated Monkeys: Neurochemical Mechanisms Studied by Intrastriatal Microdialysis , 2008, The Journal of Neuroscience.
[426] P. Christos,et al. Prospective cohort study of impulse control disorders in Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.
[427] A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease , 2005, Experimental Neurology.
[428] J. Bronstein,et al. Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease , 2006, Neurology.
[429] H. Russmann,et al. Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years , 2004, Neurology.
[430] W. Ondo,et al. Predictors of impulsivity and reward seeking behavior with dopamine agonists. , 2008, Parkinsonism & related disorders.
[431] C. Colosimo,et al. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.
[432] F. Guimarães,et al. Catalepsy induced by intra-striatal administration of nitric oxide synthase inhibitors in rats. , 2004, European journal of pharmacology.
[433] M. Cenci,et al. Rodent models of treatment-induced motor complications in Parkinson's disease. , 2009, Parkinsonism & related disorders.
[434] E. Lane,et al. l-DOPA and graft-induced dyskinesia: Different treatment, same story? , 2013, Experimental biology and medicine.
[435] Alexander Hammers,et al. Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. , 2011, Brain : a journal of neurology.
[436] S. Schiffmann,et al. Distribution of adenosine A2 receptor mRNA in the human brain , 1991, Neuroscience Letters.
[437] O. Hornykiewicz,et al. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. , 2004, Brain : a journal of neurology.
[438] Gabriel M. Belfort,et al. Npas4 Regulates a Transcriptional Program in CA3 Required for Contextual Memory Formation , 2011, Science.
[439] M. Cenci,et al. Differential Involvement of D1 and D2 Dopamine Receptors in L-DOPA-Induced Angiogenic Activity in a Rat Model of Parkinson's Disease , 2009, Neuropsychopharmacology.
[440] Marc G Caron,et al. Identification of PSD-95 as a Regulator of Dopamine-Mediated Synaptic and Behavioral Plasticity , 2004, Neuron.
[441] M. Savasta,et al. Subthalamic Stimulation-Induced Forelimb Dyskinesias Are Linked to an Increase in Glutamate Levels in the Substantia Nigra Pars Reticulata , 2006, The Journal of Neuroscience.
[442] R. Alterman,et al. Immediate and sustained relief of levodopa-induced dyskinesias after dorsal relocation of a deep brain stimulation lead. Case report. , 2004, Neurosurgical focus.
[443] M. Caron,et al. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. , 1999, Science.
[444] P. Magistretti,et al. Metabolic coupling between glia and neurons , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[445] J. Kordower,et al. Influence of cell preparation and target location on the behavioral recovery after striatal transplantation of fetal dopaminergic neurons in a primate model of Parkinson’s disease , 2008, Neurobiology of Disease.
[446] Arun Singh,et al. Dual κ‐agonist/μ‐antagonist opioid receptor modulation reduces levodopa‐induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease , 2015, Annals of neurology.
[447] David Belin,et al. Evidence for Addiction-like Behavior in the Rat , 2004, Science.
[448] E. Gatto,et al. Kleptomania, an unusual impulsive control disorder in Parkinson's disease? , 2010, Parkinsonism & related disorders.
[449] R. Kaji,et al. Which target is best for patients with Parkinson's disease? A meta-analysis of pallidal and subthalamic stimulation , 2014, Journal of Neurology, Neurosurgery & Psychiatry.
[450] L. Grégoire,et al. Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys , 2010, Neuropharmacology.
[451] N. Hattori,et al. [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease]. , 2004, Rinsho shinkeigaku = Clinical neurology.
[452] G. Deuschl,et al. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6‐month randomized placebo‐controlled double‐blind study in Germany and Austria (Celomen study) , 2002, Acta neurologica Scandinavica.
[453] H. Reichmann,et al. Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta‐analysis of levodopa‐controlled trials , 2014, European journal of neurology.
[454] J. Benovic,et al. Mechanism of Quenching of Phototransduction , 1997, The Journal of Biological Chemistry.
[455] Brice de la Crompe,et al. Inhibiting Lateral Habenula Improves L-DOPA–Induced Dyskinesia , 2016, Biological Psychiatry.
[456] H. Loh,et al. Molecular mechanisms and regulation of opioid receptor signaling. , 2000, Annual review of pharmacology and toxicology.
[457] Robert E. Kingston,et al. Occupying chromatin: Polycomb mechanisms for getting to genomic targets, stopping transcriptional traffic, and staying put. , 2013, Molecular cell.
[458] J. Brotchie,et al. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study , 2001, Neurology.
[459] G. Gerhardt,et al. Serotonergic nerve fibers in l-DOPA-derived dopamine release and dyskinesia , 2014, Neuroscience.
[460] A. Lawrence,et al. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? , 2003, The Lancet Neurology.
[461] A. Schrag,et al. Low-dose olanzapine for levodopa induced dyskinesias , 2000, Neurology.
[462] M. Andersson,et al. Persistent changes in striatal gene expression induced by long‐term l‐DOPA treatment in a rat model of Parkinson's disease , 2001, The European journal of neuroscience.
[463] P. Calabresi,et al. A Critical Role of the Nitric Oxide/cGMP Pathway in Corticostriatal Long-Term Depression , 1999, The Journal of Neuroscience.
[464] S. Rasmussen,et al. Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.
[465] A. Strafella,et al. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[466] P. Greengard,et al. DARPP-32 mediates serotonergic neurotransmission in the forebrain , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[467] F. Fadda,et al. Role of striatal l‐DOPA in the production of dyskinesia in 6‐hydroxydopamine lesioned rats , 2006, Journal of neurochemistry.
[468] Qin Li,et al. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. , 2007, Neurobiology of disease.
[469] M. Decker,et al. The α7 Nicotinic Receptor Agonist ABT-107 Decreases l-Dopa–Induced Dyskinesias in Parkinsonian Monkeys , 2014, The Journal of Pharmacology and Experimental Therapeutics.
[470] J. Anselmo-Franci,et al. Effects of prolonged neuronal nitric oxide synthase inhibition on the development and expression of l-DOPA-induced dyskinesia in 6-OHDA-lesioned rats , 2015, Neuropharmacology.
[471] L. Groc,et al. Surface trafficking of NMDA receptors: gathering from a partner to another. , 2014, Seminars in cell & developmental biology.
[472] J. Meerwaldt,et al. Factors that influence the occurrence of response variations in Parkinson's disease , 1987, Annals of neurology.
[473] A. Cerasa,et al. Prefrontal thickening in PD with levodopa-induced dyskinesias: new evidence from cortical thickness measurement. , 2013, Parkinsonism & related disorders.
[474] M. Cenci,et al. Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications , 2014, Front. Neurol..
[475] R. Desimone,et al. Internal globus pallidus discharge is nearly suppressed during levodopa‐induced dyskinesias , 1999, Annals of neurology.
[476] Danqing Xiao,et al. Forebrain Adenosine A2A Receptors Contribute to l-3,4-Dihydroxyphenylalanine-Induced Dyskinesia in Hemiparkinsonian Mice , 2006, The Journal of Neuroscience.
[477] Hagai Bergman,et al. Comparison of MPTP-induced changes in spontaneous neuronal discharge in the internal pallidal segment and in the substantia nigra pars reticulata in primates , 1999, Experimental Brain Research.
[478] C. Barnum,et al. Effects of the beta‐adrenergic receptor antagonist Propranolol on dyskinesia and L‐DOPA‐induced striatal DA efflux in the hemi‐parkinsonian rat , 2015, Journal of neurochemistry.
[479] A. Graybiel. Building action repertoires: memory and learning functions of the basal ganglia , 1995, Current Opinion in Neurobiology.
[480] F. Monsma,et al. Rats rapidly develop tolerance to the locomotor-inhibiting effects of the novel neuropeptide orphanin FQ , 1996, Neurochemical Research.
[481] C. Phelix,et al. Monoamine innervation of bed nucleus of stria terminalis: An electron microscopic investigation , 1992, Brain Research Bulletin.
[482] Erwan Bezard,et al. Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with l-dopa–induced dyskinesia , 2010, Proceedings of the National Academy of Sciences.
[483] G Baselli,et al. Altered subthalamo-pallidal synchronisation in parkinsonian dyskinesias , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[484] M. Contin,et al. Pharmacokinetics of levodopa , 2010, Journal of Neurology.
[485] P. Ravenscroft,et al. Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[486] Harald Binder,et al. Quality of life in Parkinson's disease patients with motor fluctuations and dyskinesias in five European countries. , 2014, Parkinsonism & related disorders.
[487] Yu Tian Wang,et al. Dual Regulation of NMDA Receptor Functions by Direct Protein-Protein Interactions with the Dopamine D1 Receptor , 2002, Cell.
[488] C. Gerfen,et al. D1 and D2 dopamine receptor function in the striatum: coactivation of D1- and D2-dopamine receptors on separate populations of neurons results in potentiated immediate early gene response in D1-containing neurons , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[489] Regina Katzenschlager,et al. The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[490] P. Jenner,et al. L-Dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations , 2001, Psychopharmacology.
[491] I. Mitchell,et al. Reversal of Parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission: Potential mechanisms of action , 1997, Neuroscience & Biobehavioral Reviews.
[492] I. Forgacs,et al. Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life , 2009, Movement disorders : official journal of the Movement Disorder Society.
[493] J. Yakel,et al. Desensitization of nicotinic ACh receptors: shaping cholinergic signaling , 2005, Trends in Neurosciences.
[494] T. Itoh,et al. l-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model , 2014, Pharmacology Biochemistry and Behavior.
[495] M. Farrer,et al. A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson's disease , 2009, Journal of Neurology, Neurosurgery & Psychiatry.
[496] Sachie K. Ogawa,et al. Whole-Brain Mapping of Direct Inputs to Midbrain Dopamine Neurons , 2012, Neuron.
[497] Y. Smith,et al. Dopaminergic denervation and spine loss in the striatum of MPTP-treated monkeys , 2009, Experimental Neurology.
[498] C. McClung,et al. DeltaFosB: a molecular switch for long-term adaptation in the brain. , 2004, Brain research. Molecular brain research.
[499] M. Caron,et al. Synergistic regulation of beta2-adrenergic receptor sequestration: intracellular complement of beta-adrenergic receptor kinase and beta-arrestin determine kinetics of internalization. , 1997, Molecular pharmacology.
[500] J. Girault,et al. Mitogen- and stress-activated protein kinase 1 is required for specific signaling responses in dopamine-denervated mouse striatum, but is not necessary for l-DOPA-induced dyskinesia , 2014, Neuroscience Letters.
[501] P. Jenner,et al. The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. , 2003, Parkinsonism & related disorders.
[502] S. Bassett,et al. Clinical features associated with impulse control disorders in Parkinson disease , 2006, Neurology.
[503] M. Nirenberg,et al. Dopamine agonist withdrawal syndrome in Parkinson disease. , 2010, Archives of neurology.
[504] Denis Hervé,et al. Gαolf Mutation Allows Parsing the Role of cAMP-Dependent and Extracellular Signal-Regulated Kinase-Dependent Signaling in l-3,4-Dihydroxyphenylalanine-Induced Dyskinesia , 2012, The Journal of Neuroscience.
[505] E. Bézard,et al. Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey , 2000, Journal of Neuroscience Methods.
[506] Epilepsy: from newly diagnosed to treatment-resistant disease , 2011, The Lancet Neurology.
[507] E. Ongini,et al. Persistent Behavioral Sensitization to Chronic l-DOPA Requires A2A Adenosine Receptors , 2002, The Journal of Neuroscience.
[508] Y. Agid,et al. Long‐term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[509] O. Hornykiewicz,et al. Sensitization of Dopamine‐Stimulated Adenylyl Cyclase in the Striatum of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine‐Treated Rhesus Monkeys and Patients with Idiopathic Parkinson's Disease , 1992, Journal of neurochemistry.
[510] M. Chesselet,et al. 3,4-Dihydroxyphenylalanine Reverses the Motor Deficits in Pitx3-Deficient Aphakia Mice: Behavioral Characterization of a Novel Genetic Model of Parkinson's Disease , 2005, The Journal of Neuroscience.
[511] M. Caron,et al. Receptor-specific desensitization with purified proteins. Kinase dependence and receptor specificity of beta-arrestin and arrestin in the beta 2-adrenergic receptor and rhodopsin systems. , 1992, The Journal of biological chemistry.
[512] K. Helin,et al. Polycomb group protein displacement and gene activation through MSK-dependent H3K27me3S28 phosphorylation. , 2010, Molecular cell.
[513] J. Hubble. Long-term studies of dopamine agonists , 2002, Neurology.
[514] D. Weintraub,et al. Impulse Control and Related Disorders in Parkinson's Disease. , 2017, International review of neurobiology.
[515] M. Morelli,et al. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. , 2007, European journal of pharmacology.
[516] P. Lewitt,et al. Actively Transported Levodopa Prodrug XP21279: A Study in Patients With Parkinson Disease Who Experience Motor Fluctuations , 2012, Clinical neuropharmacology.
[517] Steven W. Johnson,et al. Evaluation of Levodopa Dose and Magnitude of Dopamine Depletion as Risk Factors for Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease , 2007, Journal of Pharmacology and Experimental Therapeutics.
[518] N. Van Blercom,et al. Effects of Gabapentin on the Motor Response to Levodopa: A Double-Blind, Placebo-Controlled, Crossover Study in Patients With Complicated Parkinson Disease , 2004, Clinical neuropharmacology.
[519] M. Andersson,et al. Striatal fosB Expression Is Causally Linked with l -DOPA-Induced Abnormal Involuntary Movements and the Associated Upregulation of Striatal Prodynorphin mRNA in a Rat Model of Parkinson's Disease , 1999, Neurobiology of Disease.
[520] W. Ko,et al. Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐lesioned primate model of Parkinson's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.
[521] D. Engblom,et al. Mechanisms of Dopamine D1 Receptor-Mediated ERK1/2 Activation in the Parkinsonian Striatum and Their Modulation by Metabotropic Glutamate Receptor Type 5 , 2014, The Journal of Neuroscience.
[522] S. Deacon,et al. The challenge of selecting protein kinase assays for lead discovery optimization , 2008, Expert opinion on drug discovery.
[523] G. Calo’,et al. Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: in vitro and in vivo studies in mice , 2002, British journal of pharmacology.
[524] M. Andersson,et al. Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-DOPA treatment , 1999, Neuroscience.
[525] P. Zhuang,et al. Stimulation-Induced Dyskinesia in the Early Stage after Subthalamic Deep Brain Stimulation , 2009, Stereotactic and Functional Neurosurgery.
[526] G. Pasternak,et al. The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. , 2001, Pharmacological reviews.
[527] Intrastriatal injections of KN-93 ameliorates levodopa-induced dyskinesia in a rat model of Parkinson’s disease , 2013, Neuropsychiatric disease and treatment.
[528] R. Malenka,et al. N‐methyl‐d‐aspartate receptor‐ and metabotropic glutamate receptor‐dependent long‐term depression are differentially regulated by the ubiquitin‐proteasome system , 2009, The European journal of neuroscience.
[529] L. Grégoire,et al. Effect of l‐Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys , 2010, Journal of neurochemistry.
[530] C. Cepeda,et al. Repeated Exposure to Methamphetamine Causes Long-Lasting Presynaptic Corticostriatal Depression that Is Renormalized with Drug Readministration , 2008, Neuron.
[531] S. Houle,et al. Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD , 2010, Neurology.
[532] R. G. Robertson,et al. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine , 1989, Neuroscience.
[533] S. Papapetropoulos. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial , 2011 .
[534] L. Metman,et al. Intravenous amantadine improves levadopa‐induced dyskinesias: An acute double‐blind placebo‐controlled study , 2001, Movement disorders : official journal of the Movement Disorder Society.
[535] D. Hansel,et al. Physiology of MPTP Tremor , 2008, Movement disorders : official journal of the Movement Disorder Society.
[536] K. Dupre,et al. Role of the primary motor cortex in l-DOPA-induced dyskinesia and its modulation by 5-HT1A receptor stimulation , 2011, Neuropharmacology.
[537] M. Quik,et al. Nicotine-mediated improvement in l-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function , 2013, Neurobiology of Disease.
[538] N. Sonenberg,et al. Translational Control of Long-Lasting Synaptic Plasticity and Memory , 2009, Neuron.
[539] J. Maloteaux,et al. Altered expression of regulators of G-protein signaling (RGS) mRNAs in the striatum of rats undergoing dopamine depletion. , 2003, Biochemical pharmacology.
[540] R. Pearce. L-dopa and dyskinesias in normal monkeys. , 1999, Movement disorders : official journal of the Movement Disorder Society.
[541] J. Langston,et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. , 2004, Archives of neurology.
[542] T. Di Paolo,et al. Differential Regulation of Striatal Preproenkephalin and Preprotachykinin mRNA Levels in MPTP‐Lesioned Monkeys Chronically Treated with Dopamine D1 or D2 Receptor Agonists , 1999, Journal of neurochemistry.
[543] C. Gerfen. D1 Dopamine Receptor Supersensitivity in the Dopamine-Depleted Striatum , 2010 .
[544] R. Moratalla,et al. L-DOPA Treatment Selectively Restores Spine Density in Dopamine Receptor D2–Expressing Projection Neurons in Dyskinetic Mice , 2014, Biological Psychiatry.
[545] G. Chiara,et al. Priming of rotational behavior by a dopamine receptor agonist in hemiparkinsonian rats: Movement-dependent induction , 2009, Neuroscience.
[546] G. Collingridge,et al. Subcellular redistribution of the synapse‐associated proteins PSD‐95 and SAP97 in animal models of Parkinson&s disease and L‐DOPA‐induced dyskinesia , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[547] R. Mark Wightman,et al. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter , 1996, Nature.
[548] S. Spieker,et al. The NMDA antagonist budipine can alleviate levodopa‐induced motor fluctuations , 1999, Movement disorders : official journal of the Movement Disorder Society.
[549] L. Tremblay,et al. Tremor‐related activity of neurons in the ‘motor’ thalamus: changes in firing rate and pattern in the MPTP vervet model of parkinsonism , 2003, The European journal of neuroscience.
[550] D. Black,et al. A review of compulsive buying disorder. , 2007, World psychiatry : official journal of the World Psychiatric Association.
[551] J. Brotchie,et al. Reduction of l-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease , 2010, Journal of Pharmacology and Experimental Therapeutics.
[552] L. Tremblay,et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. , 2010, Brain : a journal of neurology.
[553] A. Björklund,et al. L‐DOPA‐induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin‐ and glutamic acid decarboxylase mRNA , 1998, The European journal of neuroscience.
[554] J. Tesmer,et al. A Surface of the Kinase Domain Critical for the Allosteric Activation of G Protein-coupled Receptor Kinases* , 2009, The Journal of Biological Chemistry.
[555] C. Hammond,et al. Dual Effect of High-Frequency Stimulation on Subthalamic Neuron Activity , 2003, The Journal of Neuroscience.
[556] W. Danysz,et al. Antagonism of metabotropic glutamate receptor type 5 attenuates l‐DOPA‐induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson’s disease , 2007, Journal of neurochemistry.
[557] L. Olson,et al. Substantia nigra transplants into denervated striatum of the rat: Ultrastructure of graft and host interconnections , 1985, The Journal of comparative neurology.
[558] Christos Tsironis,et al. Investigation of the antidyskinetic site of action of metabotropic and ionotropic glutamate receptor antagonists. Intracerebral infusions in 6-hydroxydopamine-lesioned rats with levodopa-induced dyskinesia. , 2012, European journal of pharmacology.
[559] E I Canela,et al. Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[560] Y. Hurd,et al. Coadministration of (−)-OSU6162 with l -DOPA Normalizes Preproenkephalin mRNA Expression in the Sensorimotor Striatum of Primates with Unilateral 6-OHDA Lesions , 2001, Experimental Neurology.
[561] M. Olianas,et al. Activation of nociceptin/orphanin FQ‐NOP receptor system inhibits tyrosine hydroxylase phosphorylation, dopamine synthesis, and dopamine D1 receptor signaling in rat nucleus accumbens and dorsal striatum , 2008, Journal of neurochemistry.
[562] T. Sotnikova,et al. An Akt/β-Arrestin 2/PP2A Signaling Complex Mediates Dopaminergic Neurotransmission and Behavior , 2005, Cell.
[563] A. Mushegian,et al. G protein-coupled receptor kinases: more than just kinases and not only for GPCRs. , 2012, Pharmacology & therapeutics.
[564] A. Björklund,et al. mTOR inhibition alleviates L-DOPA-induced dyskinesia in parkinsonian rats. , 2013, Journal of Parkinson's disease.
[565] S. Mangiavacchi,et al. D1 dopamine receptor stimulation increases the rate of AMPA receptor insertion onto the surface of cultured nucleus accumbens neurons through a pathway dependent on protein kinase A , 2004, Journal of neurochemistry.
[566] P. Jenner. Molecular mechanisms of L-DOPA-induced dyskinesia , 2008, Nature Reviews Neuroscience.
[567] P. Singh,et al. Molecular basis for activation of G protein‐coupled receptor kinases , 2010, The EMBO journal.
[568] K. Fuxe,et al. Stimulation of adenosine A2 receptors induces catalepsy , 1991, Neuroscience Letters.
[569] Mark Hallett,et al. Impulse control disorders in Parkinson's disease: recent advances. , 2011, Current opinion in neurology.
[570] Antonio Oliviero,et al. Oscillatory pallidal local field potential activity inversely correlates with limb dyskinesias in Parkinson's disease , 2005, Experimental Neurology.
[571] L. Bard,et al. Glutamate receptor dynamics and protein interaction: Lessons from the NMDA receptor , 2011, Molecular and Cellular Neuroscience.
[572] T. Daigle,et al. Targeting β-arrestin2 in the treatment of l-DOPA–induced dyskinesia in Parkinson’s disease , 2015, Proceedings of the National Academy of Sciences.
[573] P. Redgrave,et al. What is reinforced by phasic dopamine signals? , 2008, Brain Research Reviews.
[574] L. Metman,et al. A trial of dextromethorphan in parkinsonian patients with motor response complications , 1998, Movement disorders : official journal of the Movement Disorder Society.
[575] Kwang-Soo Kim,et al. Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. , 2003, Brain research. Molecular brain research.
[576] E. Nestler,et al. Elevated levels of ΔFosB and RGS9 in striatum in Parkinson’s disease , 2001, Biological Psychiatry.
[577] J. Nutt,et al. Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. , 2001, Archives of neurology.
[578] M. Morari,et al. Differential involvement of Ras-GRF1 and Ras-GRF2 in L-DOPA-induced dyskinesia , 2015, Annals of clinical and translational neurology.
[579] E. Bézard,et al. Effect of the D3 Dopamine Receptor Partial Agonist BP897 [N-[4-(4-(2-Methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on l-3,4-Dihydroxyphenylalanine-Induced Dyskinesias and Parkinsonism in Squirrel Monkeys , 2004, Journal of Pharmacology and Experimental Therapeutics.
[580] T. Chase,et al. Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and l-DOPA administration , 1998, Brain Research.
[581] A. Goodgold,et al. Treatment failures with levodopa in parkinsonism , 1972, Neurology.
[582] M. Cyr,et al. Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat , 2010, Neurobiology of Disease.
[583] E. Bézard,et al. D1 Dopamine Receptor-Mediated LTP at GABA Synapses Encodes Motivation to Self-Administer Cocaine in Rats , 2013, The Journal of Neuroscience.
[584] H. Lindgren,et al. A model of l-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function , 2004, Neurobiology of Disease.
[585] S. L. Kaplan. A Self-Rated Scale for Obsessive-Compulsive Disorder. , 1994, Journal of clinical psychology.
[586] C. Konradi,et al. Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. , 2010, Progress in brain research.
[587] S. Singer,et al. The fluid mosaic model of the structure of cell membranes. , 1972, Science.
[588] R. Moratalla,et al. Activation of DREAM (Downstream Regulatory Element Antagonistic Modulator), a Calcium-Binding Protein, Reduces L-DOPA-Induced Dyskinesias in Mice , 2015, Biological Psychiatry.
[589] E. Azmitia,et al. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat , 1978, The Journal of comparative neurology.
[590] M. Smidt,et al. Molecular mechanisms underlying midbrain dopamine neuron development and function. , 2003, European journal of pharmacology.
[591] J. Brotchie,et al. Effect of Repeated l -DOPA, Bromocriptine, or Lisuride Administration on Preproenkephalin-A and Preproenkephalin-B mRNA Levels in the Striatum of the 6-Hydroxydopamine-Lesioned Rat , 1999, Experimental Neurology.
[592] S. Cragg,et al. Nicotine amplifies reward-related dopamine signals in striatum , 2004, Nature Neuroscience.
[593] J. Rothwell,et al. Abnormal bidirectional plasticity-like effects in Parkinson's disease. , 2011, Brain : a journal of neurology.
[594] L. Groc,et al. Regulation of Dopamine D1 Receptor Dynamics within the Postsynaptic Density of Hippocampal Glutamate Synapses , 2013, PloS one.
[595] E. Tronci,et al. Effect of selective and non-selective serotonin receptor activation on l-DOPA-induced therapeutic efficacy and dyskinesia in parkinsonian rats , 2015, Behavioural Brain Research.
[596] K. Steece-Collier,et al. Anatomy of Graft-induced Dyskinesias: Circuit Remodeling in the Parkinsonian Striatum. , 2012, Basal ganglia.
[597] N. Quinn,et al. L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates , 2007, Journal of neural transmission.
[598] T. Chase,et al. Effects of serotonin 5‐HT1A agonist in advanced Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.
[599] P. Calabresi,et al. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap , 2010, The Lancet Neurology.
[600] K. Palczewski,et al. Mechanism of rhodopsin kinase activation. , 1991, The Journal of biological chemistry.
[601] M. Collu,et al. Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease , 2014, Neuroscience.
[602] R. Robertson,et al. MPTP-Induced Parkinsonism in the Monkey: Neurochemical Pathology, Complications of Treatment and Pathophysiological Mechanisms , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[603] M. Amalric,et al. Cellular and Behavioral Outcomes of Dorsal Striatonigral Neuron Ablation: New Insights into Striatal Functions , 2014, Neuropsychopharmacology.
[604] Gerfen Cr. Dopamine-mediated gene regulation in models of Parkinson's disease. , 2000 .
[605] C. Olanow,et al. Orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.
[606] F. Turkheimer,et al. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease , 2011, Neurology.
[607] J. Obeso,et al. Impairment of brain vessels may contribute to mortality in patients with Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.
[608] A. Serretti,et al. Specificity profile of venlafaxine and sertraline in major depression: metaregression of double-blind, randomized clinical trials. , 2014, The international journal of neuropsychopharmacology.
[609] A. Rajput,et al. Chronic low‐dose levodopa therapy in Parkinson's disease , 1984, Neurology.
[610] T. Chase,et al. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson’s disease , 2003, Experimental Neurology.
[611] D. D. Di Monte,et al. Nicotine reduces levodopa‐induced dyskinesias in lesioned monkeys , 2007, Annals of neurology.
[612] C. Capper-Loup,et al. Spontaneous locomotor activity and L-DOPA-induced dyskinesia are not linked in 6-OHDA parkinsonian rats , 2014, Front. Behav. Neurosci..
[613] D. Hansel,et al. Subthalamic high frequency stimulation resets subthalamic firing and reduces abnormal oscillations. , 2005, Brain : a journal of neurology.
[614] G. Bernardi,et al. Lowered cAMP and cGMP signalling in the brain during levodopa‐induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms , 2008, The European journal of neuroscience.
[615] W. Ko,et al. Effects of l-tryptophan on l-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease , 2014, Neuroscience Letters.
[616] L. Bour,et al. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial , 2013, The Lancet Neurology.
[617] D. Lindenbach,et al. Side effect profile of 5‐HT treatments for Parkinson's disease and L‐DOPA‐induced dyskinesia in rats , 2015, British journal of pharmacology.
[618] M. Kathmann,et al. Inhibition of striatal and retinal dopamine release via nociceptin/orphanin FQ receptors , 2002, British journal of pharmacology.
[619] Grant D. Huang,et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. , 2010, The New England journal of medicine.
[620] I. Mitchell,et al. Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) , 1987, Journal of the Neurological Sciences.
[621] P. Greengard,et al. Allosteric changes of the NMDA receptor trap diffusible dopamine 1 receptors in spines , 2006, European Neuropsychopharmacology.
[622] Henrik Alm,et al. Striatal Proteomic Analysis Suggests that First L-Dopa Dose Equates to Chronic Exposure , 2008, PloS one.
[623] Y. Mizuno,et al. Clinical efficacy of istradefylline (KW‐6002) in Parkinson's disease: A randomized, controlled study , 2010, Movement disorders : official journal of the Movement Disorder Society.
[624] S. Fasano,et al. Ras–ERK Signaling in Behavior: Old Questions and New Perspectives , 2011, Front. Behav. Neurosci..
[625] Daniela Berg,et al. Treatment of Levodopa-Induced Dyskinesias : Results of 2 Randomized Controlled Trials , 2011 .
[626] V. Sossi,et al. Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications. , 2006, Brain : a journal of neurology.
[627] Hiroyuki Okuno,et al. Regulation and function of immediate-early genes in the brain: Beyond neuronal activity markers , 2011, Neuroscience Research.
[628] D. Calne,et al. The long-term response to levodopa in dopa-responsive dystonia. , 2001, Parkinsonism & related disorders.
[629] E. Bézard,et al. Could the serotonin theory give rise to a treatment for levodopa-induced dyskinesia in Parkinson's disease? , 2015, Brain : a journal of neurology.
[630] Christian Hauptmann,et al. Coordinated reset has sustained aftereffects in Parkinsonian monkeys , 2012, Annals of neurology.
[631] J. Lanciego,et al. l-DOPA-treatment in primates disrupts the expression of A2A adenosine–CB1 cannabinoid–D2 dopamine receptor heteromers in the caudate nucleus , 2014, Neuropharmacology.
[632] Niall Quinn,et al. Young onset Parkinson's disease , 1987, Movement disorders : official journal of the Movement Disorder Society.
[633] Vesna Sossi,et al. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study , 2007, Annals of neurology.
[634] E. Bézard,et al. Compensatory mechanisms in experimental and human Parkinsonism: towards a dynamic approach , 1998, Progress in Neurobiology.
[635] E. Tronci,et al. Serotonin System Implication in l-DOPA-Induced Dyskinesia: From Animal Models to Clinical Investigations , 2014, Front. Neurol..
[636] M. Quik,et al. Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats , 2011, Neuropharmacology.
[637] U. Gschwandtner,et al. Pathologic gambling in patients with Parkinson's disease. , 2001, Clinical neuropharmacology.
[638] High frequency stimulation of the subthalamic nucleus and levodopa induced dyskinesias in Parkinson's disease , 2000, Journal of neurology, neurosurgery, and psychiatry.
[639] J. Benovic,et al. Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor. , 1996, Nature.
[640] A. Björklund,et al. Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia , 2013, Neuroscience Research.
[641] O. Hornykiewicz,et al. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey , 1991, Neuroscience.
[642] R. Arai,et al. l-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study , 1995, Neuroscience Letters.
[643] Haruhiko Kishima,et al. Functional Recovery in a Primate Model of Parkinson's Disease following Motor Cortex Stimulation , 2004, Neuron.
[644] G. Meredith,et al. The synaptic impact of the host immune response in a parkinsonian allograft rat model: Influence on graft-derived aberrant behaviors , 2008, Neurobiology of Disease.
[645] M. Quik,et al. Nicotine reduces established levodopa‐induced dyskinesias in a monkey model of Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.
[646] J. Brotchie,et al. Ropinirole versus l-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia , 2004, Experimental Neurology.
[647] J. C. Stoof,et al. Priming of 6-hydroxydopamine-lesioned rats with L-DOPA or quinpirole results in an increase in dopamine D1 receptor-dependent cyclic AMP production in striatal tissue. , 1997, European journal of pharmacology.
[648] G. Fisone,et al. Group III and subtype 4 metabotropic glutamate receptor agonists: Discovery and pathophysiological applications in Parkinson's disease , 2013, Neuropharmacology.
[649] M. Morelli,et al. Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons , 2013, Experimental Neurology.
[650] G. Fisone,et al. L-DOPA-Induced Dyskinesia and Abnormal Signaling in Striatal Medium Spiny Neurons: Focus on Dopamine D1 Receptor-Mediated Transmission , 2011, Front. Behav. Neurosci..
[651] D. Siderovski,et al. The GAPs, GEFs, and GDIs of heterotrimeric G-protein alpha subunits , 2005, International journal of biological sciences.
[652] S. Iversen,et al. Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. , 1990, Clinical neuropharmacology.
[653] A. Deutch,et al. Dopamine depletion alters phosphorylation of striatal proteins in a model of Parkinsonism , 2005, The European journal of neuroscience.
[654] E. Bézard,et al. Compensatory Mechanisms in Experimental and Human Parkinsonism , 2009 .
[655] P. Greengard,et al. Distinct Levels of Dopamine Denervation Differentially Alter Striatal Synaptic Plasticity and NMDA Receptor Subunit Composition , 2010, The Journal of Neuroscience.
[656] C. Lindsley,et al. Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and l-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist , 2015, Neuropharmacology.
[657] L. Grégoire,et al. The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys. , 2011, Parkinsonism & related disorders.
[658] M. Quik,et al. Continuous and Intermittent Nicotine Treatment Reduces l-3,4-Dihydroxyphenylalanine (l-DOPA)-Induced Dyskinesias in a Rat Model of Parkinson's Disease , 2008, Journal of Pharmacology and Experimental Therapeutics.
[659] J. Holden,et al. 6‐[18F]fluoro‐L‐DOPA PET studies of the turnover of dopamine in MPTP‐induced parkinsonism in monkeys , 1998, Synapse.
[660] A. Sadikot,et al. Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons , 2003, Development.
[661] S. Grant,et al. A role for the Ras signalling pathway in synaptic transmission and long-term memory , 1997, Nature.
[662] M. Decker,et al. ABT‐089 and ABT‐894 reduce levodopa‐induced dyskinesias in a monkey model of Parkinson's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.
[663] M. Marks,et al. L-DOPA treatment modulates nicotinic receptors in monkey striatum. , 2003, Molecular pharmacology.
[664] M. Morelli,et al. Different responsiveness of striatonigral and striatopallidal neurons to L‐DOPA after a subchronic intermittent L‐DOPA treatment , 2005, The European journal of neuroscience.
[665] J. Brotchie,et al. L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat. , 2015, Behavioural pharmacology.
[666] E. Bézard,et al. Single-molecule imaging of the functional crosstalk between surface NMDA and dopamine D1 receptors , 2013, Proceedings of the National Academy of Sciences.
[667] A. Björklund,et al. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa‐induced dyskinesia , 2013, Movement disorders : official journal of the Movement Disorder Society.
[668] G. Kolata. Monkey model of Parkinson's disease. , 1983, Science.
[669] D. Riche,et al. Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons , 1993, Neuroscience.
[670] H. Bergman,et al. Pathological synchronization in Parkinson's disease: networks, models and treatments , 2007, Trends in Neurosciences.
[671] D J Brooks,et al. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa‐induced dyskinesias , 1997, Annals of neurology.
[672] J. Brotchie,et al. Antiparkinsonian Actions of Ifenprodil in the MPTP-Lesioned Marmoset Model of Parkinson's Disease , 2000, Experimental Neurology.
[673] M. Matsunaga,et al. Activation of 5‐HT1A but not 5‐HT1B receptors attenuates an increase in extracellular dopamine derived from exogenously administered l‐DOPA in the striatum with nigrostriatal denervation , 2001, Journal of neurochemistry.
[674] E. Bézard,et al. Reinforcing properties of Pramipexole in normal and parkinsonian rats , 2013, Neurobiology of Disease.
[675] J. Nyengaard,et al. Endothelial Proliferation and Increased Blood–Brain Barrier Permeability in the Basal Ganglia in a Rat Model of 3,4-Dihydroxyphenyl-l-Alanine-Induced Dyskinesia , 2006, The Journal of Neuroscience.
[676] P. Calabresi,et al. Abnormal Ca2+-Calmodulin-Dependent Protein Kinase II Function Mediates Synaptic and Motor Deficits in Experimental Parkinsonism , 2004, The Journal of Neuroscience.
[677] S. Rosset,et al. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation. , 2012, Parkinsonism & related disorders.
[678] Ann M Graybiel,et al. Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapy , 2009, Proceedings of the National Academy of Sciences.
[679] E. Bézard,et al. Pattern of levodopa‐induced striatal changes is different in normal and MPTP‐lesioned mice , 2003, Journal of neurochemistry.
[680] S. Fleming. Cardiovascular autonomic dysfunction in animal models of Parkinson's disease. , 2011, Journal of Parkinson's disease.
[681] G. Fisone,et al. A Role for Mitogen- and Stress-Activated Kinase 1 in L-DOPA–Induced Dyskinesia and ∆FosB Expression , 2016, Biological Psychiatry.
[682] M. Cenci,et al. l‐DOPA‐induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson’s disease: temporal and quantitative relationship to the expression of dyskinesia , 2010, Journal of neurochemistry.
[683] L. Savage,et al. Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats , 2011, Experimental Neurology.
[684] A. Triller,et al. Fast and reversible trapping of surface glycine receptors by gephyrin , 2001, Nature Neuroscience.
[685] M. Cenci,et al. In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to l-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels , 2012, Neurobiology of Disease.
[686] Qin Li,et al. Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson's disease and l-DOPA-induced dyskinesia , 2014, Neurobiology of Disease.
[687] Joshua L. Plotkin,et al. Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia , 2014, Nature Communications.
[688] C. Waters,et al. Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment , 1997, Neurology.
[689] K. Fuxe,et al. Identification of Dopamine D1–D3 Receptor Heteromers , 2008, Journal of Biological Chemistry.
[690] R. Cantello. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies , 2000, Journal of neurology, neurosurgery, and psychiatry.
[691] Stephen Tisch,et al. The latest evidence on target selection in deep brain stimulation for Parkinson’s disease , 2014, Journal of Clinical Neuroscience.
[692] S. Grady,et al. Role for α6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice , 2012, Neuropharmacology.
[693] C. Verney,et al. G(olf) and Gs in rat basal ganglia: possible involvement of G(olf) in the coupling of dopamine D1 receptor with adenylyl cyclase , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[694] J. Langston,et al. Dyskinesias in normal squirrel monkeys induced by nomifensine and levodopa , 2005, Neuropharmacology.
[695] P. Stanzione,et al. Evidence of an association between sleep and levodopa-induced dyskinesia in an animal model of Parkinson's disease , 2015, Neurobiology of Aging.
[696] E. Bézard,et al. Dopamine Transporter Binding Is Unaffected by L-DOPA Administration in Normal and MPTP-Treated Monkeys , 2010, PloS one.
[697] A. Nishi,et al. PKA-Dependent Phosphorylation of Ribosomal Protein S6 Does Not Correlate with Translation Efficiency in Striatonigral and Striatopallidal Medium-Sized Spiny Neurons , 2015, Journal of Neuroscience.
[698] O. Rascol,et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double‐blind placebo‐controlled trial , 2007, Movement disorders : official journal of the Movement Disorder Society.
[699] G. Reynolds,et al. [3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. , 1985, European journal of pharmacology.
[700] C. Mariani,et al. Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome , 2013, Journal of Neurology, Neurosurgery & Psychiatry.
[701] I. Mitchell,et al. Regional brain uptake of 2-deoxyglucose in N -methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)—induced parkinsonism in the macaque monkey , 1985, Neuropharmacology.
[702] C. V. van Duijn,et al. Parkinson's disease: piecing together a genetic jigsaw. , 2003, Brain : a journal of neurology.
[703] S. Grady,et al. Nicotine Reduces l-DOPA-Induced Dyskinesias by Acting at β2* Nicotinic Receptors , 2011, Journal of Pharmacology and Experimental Therapeutics.
[704] E. Nestler,et al. Cloning and Characterization of RGS9-2: A Striatal-Enriched Alternatively Spliced Product of the RGS9 Gene , 1999, The Journal of Neuroscience.
[705] L. Metman,et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease , 1998, Neurology.
[706] W R Woodward,et al. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. , 1984, The New England journal of medicine.
[707] D. Grandy,et al. Orphanin FQ: A Neuropeptide That Activates an Opioidlike G Protein-Coupled Receptor , 1995, Science.
[708] E. Bézard,et al. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L‐dopa and ropinirole in the MPTP‐lesioned marmoset , 2003, Movement disorders : official journal of the Movement Disorder Society.
[709] Y. Geda,et al. Pathological gambling caused by drugs used to treat Parkinson disease. , 2005, Archives of neurology.
[710] W. Wetsel,et al. Dopamine-Independent Locomotor Actions of Amphetamines in a Novel Acute Mouse Model of Parkinson Disease , 2005, PLoS biology.
[711] W. Ko,et al. RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease , 2014, Neurobiology of Disease.
[712] B. Balleine,et al. Lesions of dorsolateral striatum preserve outcome expectancy but disrupt habit formation in instrumental learning , 2004, The European journal of neuroscience.
[713] U Wilden,et al. Duration and amplitude of the light-induced cGMP hydrolysis in vertebrate photoreceptors are regulated by multiple phosphorylation of rhodopsin and by arrestin binding. , 1995, Biochemistry.
[714] J C Mazziotta,et al. The lennox‐gastaut syndrome: Metabolic subtypes determined by 2‐deoxy‐2 [18F]fluoro‐d‐glucose positron emission tomography , 1987, Annals of neurology.
[715] Britt Mellström,et al. DREAM is a Ca2+-regulated transcriptional repressor , 1999, Nature.
[716] W. Weiner,et al. Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study) , 2012, Neurology.
[717] A. Carlsson,et al. 3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists , 1957, Nature.
[718] Y. Michotte,et al. MK801 suppresses the l-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats , 2002, Brain Research.
[719] J. Dostrovsky,et al. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients. , 2009, Brain : a journal of neurology.
[720] Qin Li,et al. Widespread Monoaminergic Dysregulation of Both Motor and Non-Motor Circuits in Parkinsonism and Dyskinesia. , 2015, Cerebral cortex.
[721] S. Davis,et al. Regulated transcription of the immediate‐early gene Zif268: Mechanisms and gene dosage‐dependent function in synaptic plasticity and memory formation , 2002, Hippocampus.
[722] J. Jin,et al. Inhibitory effect of capsaicin on the ascending pathway of the guinea-pig ileum and antagonism of this effect by ruthenium red. , 1990, European journal of pharmacology.
[723] Paola Savoia,et al. The tyrosine phosphatase Shp‐2 interacts with the dopamine D1 receptor and triggers D1‐mediated Erk signaling in striatal neurons , 2011, Journal of neurochemistry.
[724] P. Salin,et al. Chronic l‐DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease , 2004, The European journal of neuroscience.
[725] Y. Agid,et al. A multidisciplinary study of patients with early-onset PD with and without parkin mutations , 2009, Neurology.
[726] P. Calabresi,et al. Striatal synaptic plasticity: Implications for motor learning and Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.
[727] J. Molgó,et al. Ultrastructure of botulinum type-A poisoned frog motor nerve terminals after enhanced quantal transmitter release caused by carbonyl cyanide m-chlorophenylhydrazone , 1991, Neuroscience Letters.
[728] H. Groenewegen,et al. [Impulse control disorders in Parkinson's disease]. , 2011, Tijdschrift voor psychiatrie.
[729] V. Voon,et al. Medication-related impulse control and repetitive behaviors in Parkinson's disease , 2007, Current opinion in neurology.
[730] Z. F. H. Cao,et al. Dopamine‐dependent motor learning: Insight into levodopa's long‐duration response , 2009, Annals of neurology.
[731] P. Pollak,et al. Psychostimulant effect of levodopa: reversing sensitisation is possible , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[732] Qin Li,et al. Striatal Overexpression of ΔJunD Resets L-DOPA-Induced Dyskinesia in a Primate Model of Parkinson Disease , 2009, Biological Psychiatry.
[733] V. Höllt. Opioid peptide processing and receptor selectivity. , 1986, Annual review of pharmacology and toxicology.
[734] M. Stacy,et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial , 2013, The Lancet Neurology.
[735] W. Danysz,et al. Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: Further validation of the rat dyskinesia model , 2007, Behavioural Brain Research.
[736] Fair M. Vassoler,et al. Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia. , 2011, Brain : a journal of neurology.
[737] Charles Howard Adler,et al. Randomized, Placebo-Controlled Study of Tolcapone in Patients With Fluctuating Parkinson Disease Treated With Levodopa-Carbidopa , 1998 .
[738] J. Brotchie,et al. The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease , 2013, Pharmacological Reviews.
[739] A. Korczyn,et al. Sequence Variants in SLC6A3, DRD2, and BDNF Genes and Time to Levodopa-Induced Dyskinesias in Parkinson’s Disease , 2014, Journal of Molecular Neuroscience.
[740] G. Fisone,et al. HDAC inhibitors conquer polycomb proteins , 2010 .
[741] Vesna Sossi,et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. , 2004, Brain : a journal of neurology.
[742] C. Peretz,et al. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson’s disease , 2004, Journal of Neural Transmission.
[743] E. Kultalahti,et al. Twelve‐month safety of entacapone in patients with Parkinson’s disease , 2001, European journal of neurology.
[744] A. Newman-Tancredi,et al. Activity of serotonin 5-HT1A receptor ‘biased agonists’ in rat models of Parkinson's disease and l-DOPA-induced dyskinesia , 2015, Neuropharmacology.
[745] A. Lawrence,et al. Compulsive use of dopaminergic drug therapy in Parkinson's disease: Reward and anti‐reward , 2010, Movement disorders : official journal of the Movement Disorder Society.
[746] O. Rascol,et al. A proof‐of‐concept, randomized, placebo‐controlled, multiple cross‐overs (n‐of‐1) study of naftazone in Parkinson’s disease , 2012, Fundamental & clinical pharmacology.
[747] Jungsu S. Oh,et al. Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease , 2014, Neurology.
[748] P. Gubellini,et al. High-Frequency Stimulation of the Subthalamic Nucleus Potentiates l-DOPA-Induced Neurochemical Changes in the Striatum in a Rat Model of Parkinson's Disease , 2007, The Journal of Neuroscience.
[749] Okihide Hikosaka,et al. Habenula: Crossroad between the Basal Ganglia and the Limbic System , 2008, The Journal of Neuroscience.
[750] P. Calabresi,et al. Rebalance of Striatal NMDA/AMPA Receptor Ratio Underlies the Reduced Emergence of Dyskinesia During D2-Like Dopamine Agonist Treatment in Experimental Parkinson's Disease , 2012, The Journal of Neuroscience.
[751] N. Wierup,et al. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease , 2002, The European journal of neuroscience.
[752] Angus C Nairn,et al. Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[753] M. Morelli,et al. Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions , 2004, Experimental Neurology.
[754] J. Marinus,et al. Catechol‐O‐methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.
[755] T. Paolo,et al. Modeling dyskinesia in animal models of Parkinson disease , 2014, Experimental Neurology.
[756] Qin Li,et al. The 3-Hydroxy-3-Methylglutaryl-CoA Reductase Inhibitor Lovastatin Reduces Severity of l-DOPA-Induced Abnormal Involuntary Movements in Experimental Parkinson's Disease , 2008, The Journal of Neuroscience.
[757] Ryan T. Strachan,et al. Distinct Phosphorylation Sites on the β2-Adrenergic Receptor Establish a Barcode That Encodes Differential Functions of β-Arrestin , 2011, Science Signaling.
[758] A. Benazzouz,et al. High-Frequency Stimulation of the Subthalamic Nucleus and l-3,4-Dihydroxyphenylalanine Inhibit In Vivo Serotonin Release in the Prefrontal Cortex and Hippocampus in a Rat Model of Parkinson's Disease , 2010, The Journal of Neuroscience.
[759] R. Lefkowitz,et al. Emerging paradigms of β-arrestin-dependent seven transmembrane receptor signaling. , 2011, Trends in biochemical sciences.
[760] R. Roth,et al. MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys , 1990, Brain Research.
[761] Kuei Yuan Tseng,et al. Nitric Oxide–Soluble Guanylyl Cyclase–Cyclic GMP Signaling in the Striatum: New Targets for the Treatment of Parkinson's Disease? , 2011, Front. Syst. Neurosci..
[762] J. Brotchie,et al. Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time , 2011, The Journal of Neuroscience.
[763] G. Fisone,et al. Activation of metabotropic glutamate 4 receptors decreases L-DOPA-induced dyskinesia in a mouse model of Parkinson's disease. , 2011, Journal of Parkinson's disease.
[764] S. Konitsiotis,et al. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. , 1999, Archives of neurology.
[765] J A Obeso,et al. Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease. , 2006, Brain : a journal of neurology.
[766] H. Akil,et al. Opioid receptor‐like (ORL1) receptor distribution in the rat central nervous system: Comparison of ORL1 receptor mRNA expression with 125I‐[14Tyr]‐orphanin FQ binding , 1999, The Journal of comparative neurology.
[767] Cecilia Gotti,et al. Diversity of vertebrate nicotinic acetylcholine receptors , 2009, Neuropharmacology.
[768] J. Hwang,et al. Inhibition of Adenylyl Cyclase Type 5 Prevents l-DOPA-Induced Dyskinesia in an Animal Model of Parkinson's Disease , 2014, The Journal of Neuroscience.
[769] S. Kéri,et al. Delay Discounting of Reward and Caudate Nucleus Volume in Individuals with α-Synuclein Gene Duplication before and after the Development of Parkinson’s Disease , 2012, Neurodegenerative Diseases.
[770] Aaron DiAntonio,et al. Ubiquitin-dependent regulation of the synapse. , 2004, Annual review of neuroscience.
[771] F. Kolb,et al. The human cerebellum contributes to motor, emotional and cognitive associative learning. A review , 2010, Cortex.
[772] S. Kitamura,et al. Adenosine A2A Receptors Measured with [11C]TMSX PET in the Striata of Parkinson's Disease Patients , 2011, PloS one.
[773] K. L. Leenders,et al. Unilateral MPTP lesion in a rhesus monkey: effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers , 1988, Brain Research.
[774] H. Akil,et al. Nociceptin/orphanin FQ and opioid receptor‐like receptor mRNA expression in dopamine systems , 2002, The Journal of comparative neurology.
[775] Kwang-Soo Kim,et al. Dopaminergic neurons modulate GABA neuron migration in the embryonic midbrain , 2012, Development.
[776] E. Bézard,et al. Upregulation of Striatal Preproenkephalin Gene Expression Occurs before the Appearance of Parkinsonian Signs in 1-Methyl-4-phenyl- 1,2,3,6-tetrahydropyridine Monkeys , 2001, Neurobiology of Disease.
[777] K. Kieburtz,et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study , 2014, The Lancet Neurology.
[778] Qin Li,et al. PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking. , 2012, The Journal of clinical investigation.
[779] W. Schultz,et al. Deficits in behavioral initiation and execution processes in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism , 1985, Neuroscience Letters.
[780] E. Bézard,et al. Contribution of pre-synaptic mechanisms to l-DOPA-induced dyskinesia , 2011, Neuroscience.
[781] C. Konradi,et al. Spatiotemporal Pattern of Striatal ERK1/2 Phosphorylation in a Rat Model of L-DOPA–Induced Dyskinesia and the Role of Dopamine D1 Receptors , 2007, Biological Psychiatry.
[782] N. Lambert,et al. Rapid Activation of Inwardly Rectifying Potassium Channels by Immobile G-Protein-Coupled Receptors , 2006, The Journal of Neuroscience.
[783] P. Greengard,et al. Dichotomous Dopaminergic Control of Striatal Synaptic Plasticity , 2008, Science.
[784] A. Crossman,et al. Primate models of dyskinesia: The experimental approach to the study of basal ganglia-related involuntary movement disorders , 1987, Neuroscience.
[785] Bryan L. Roth,et al. Structure of the Nociceptin/Orphanin FQ Receptor in Complex with a Peptide Mimetic , 2012, Nature.
[786] A. Lang,et al. Long-term follow-up of unilateral pallidotomy in advanced Parkinson's disease. , 2000, The New England journal of medicine.
[787] O. Rascol,et al. Prevalence of orthostatic hypotension in Parkinson’s disease , 1997, Journal of neurology, neurosurgery, and psychiatry.
[788] Robert J. Lefkowitz,et al. Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands , 2009, Proceedings of the National Academy of Sciences.
[789] Hagai Bergman,et al. Dopamine Replacement Therapy Reverses Abnormal Synchronization of Pallidal Neurons in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Primate Model of Parkinsonism , 2002, The Journal of Neuroscience.
[790] R P Lesser,et al. Analysis of the clinical problems in parkinsonism and the complications of long‐term levodopa therapy , 1979, Neurology.
[791] M. Bortolanza,et al. Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease , 2015, Neurobiology of Disease.
[792] V. Francardo,et al. Animal models of l-DOPA–induced dyskinesia: an update on the current options , 2012, Neuroscience.
[793] Janet B W Williams,et al. Diagnostic and Statistical Manual of Mental Disorders , 2013 .
[794] K. Palczewski,et al. Activation of G protein-coupled receptor kinase 1 involves interactions between its N-terminal region and its kinase domain. , 2011, Biochemistry.
[795] G. Fisone,et al. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia , 2005, Experimental Neurology.
[796] E. Bézard,et al. Immediate-early gene expression in structures outside the basal ganglia is associated to l-DOPA-induced dyskinesia , 2014, Neurobiology of Disease.
[797] Stanley Fahn,et al. Dyskinesia after fetal cell transplantation for parkinsonism: A PET study , 2002, Annals of neurology.
[798] S. Kish,et al. Brain dopamine‐stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy , 2004, Annals of neurology.
[799] R. Roth,et al. Efferent synaptic connections of dopaminergic neurons grafted into the caudate nucleus of experimentally induced parkinsonian monkeys are different from those of control animals , 1998, Experimental Brain Research.
[800] W. Poewe,et al. Novel formulations and modes of delivery of levodopa , 2015, Movement disorders : official journal of the Movement Disorder Society.
[801] M. Hallett,et al. The cerebellum in Parkinson’s disease , 2013, Brain : a journal of neurology.
[802] M. Cenci,et al. Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease , 2012, Progress in Neurobiology.
[803] M. Muenter,et al. Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature , 2001, Movement disorders : official journal of the Movement Disorder Society.
[804] Ian Q. Whishaw,et al. Animal models of neurological deficits: how relevant is the rat? , 2002, Nature Reviews Neuroscience.
[805] P. Greengard,et al. Inhibition of mTOR Signaling in Parkinson’s Disease Prevents l-DOPA–Induced Dyskinesia , 2009, Science Signaling.
[806] W T Thach,et al. The cerebellum and the adaptive coordination of movement. , 1992, Annual review of neuroscience.
[807] A. D. Smith,et al. Characterization of cholinergic neurons in the rat neostriatum. A combination of choline acetyltransferase immunocytochemistry, Golgi-impregnation and electron microscopy , 1984, Neuroscience.
[808] G. Deuschl,et al. Long‐term clinical outcome in meige syndrome treated with internal pallidum deep brain stimulation , 2011, Movement disorders : official journal of the Movement Disorder Society.
[809] A. Gjedde,et al. Serotonergic modulation of receptor occupancy in rats treated with l‐DOPA after unilateral 6‐OHDA lesioning , 2012, Journal of neurochemistry.
[810] Hsin-Chieh Yeh,et al. Effect of the 2011 vs 2003 duty hour regulation-compliant models on sleep duration, trainee education, and continuity of patient care among internal medicine house staff: a randomized trial. , 2013, JAMA internal medicine.
[811] Karen L. Eskow Jaunarajs,et al. Serotonin transporter inhibition attenuates l‐DOPA‐induced dyskinesia without compromising l‐DOPA efficacy in hemi‐parkinsonian rats , 2012, The European journal of neuroscience.
[812] J. Jankovic,et al. Treatment options for Parkinson's disease , 2002, Current opinion in neurology.
[813] B Bioulac,et al. Relationship between the Appearance of Symptoms and the Level of Nigrostriatal Degeneration in a Progressive 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease , 2001, The Journal of Neuroscience.
[814] Yen F. Tai,et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease , 2006, Neurology.
[815] B Bioulac,et al. Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey. , 2001, Brain : a journal of neurology.
[816] A. Stoessl,et al. Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa , 2003, Neuroscience.
[817] S. Salvadori,et al. Nociceptin/orphanin FQ receptor ligands , 2000, Peptides.
[818] B. Sagot,et al. Similar l-dopa-stimulated motor activity in mice with adult-onset 6-hydroxydopamine-induced symmetric dopamine denervation and in transcription factor Pitx3 null mice with perinatal-onset symmetric dopamine denervation , 2015, Brain Research.
[819] C. Konradi,et al. Transcriptome analysis in a rat model of l-DOPA-induced dyskinesia , 2004, Neurobiology of Disease.
[820] A. Björklund,et al. Role of serotonin neurons in the induction of levodopa‐ and graft‐induced dyskinesias in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[821] N. Zaveri,et al. Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): Ligand-based analysis of structural factors influencing intrinsic activity at NOP , 2005, The AAPS Journal.
[822] Marc G Caron,et al. Dopaminergic Supersensitivity in G Protein-Coupled Receptor Kinase 6-Deficient Mice , 2003, Neuron.
[823] J. Bennett,et al. Suppression of dyskinesias in advanced Parkinson's disease: Moderate daily clozapine doses provide long‐term dyskinesia reduction , 1994, Movement disorders : official journal of the Movement Disorder Society.
[824] P. Jenner,et al. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease? , 2006, Experimental Neurology.
[825] E. Bézard,et al. A tale on animal models of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[826] Erwan Bezard,et al. Astrocytosis in parkinsonism: considering tripartite striatal synapses in physiopathology? , 2014, Front. Aging Neurosci..
[827] J. Brotchie,et al. Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of excitatory amino acid and dopamine transmission in the bilateral 6‐OHDA lesioned marmoset , 1995, Behavioural pharmacology.
[828] Vesna Sossi,et al. A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease , 2003, Annals of neurology.
[829] R. Hodgson,et al. A2A receptor antagonists do not induce dyskinesias in drug-naive or l-dopa sensitized rats , 2013, Brain Research Bulletin.
[830] James Parkinson,et al. An essay on the shaking palsy. 1817. , 2002, The Journal of neuropsychiatry and clinical neurosciences.
[831] Duncan P. Taylor. Buspirone, a new approach to the treatment of anxiety , 1988, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[832] Y. Agid,et al. Effects of etybenzatropine and diazepam on levodopa‐induced diphasic dyskinesias in Parkinson's disease , 1989, Movement disorders : official journal of the Movement Disorder Society.
[833] P. Lewitt,et al. Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics , 2015, Movement disorders : official journal of the Movement Disorder Society.
[834] R. Roth,et al. Behavioral Effects of MPTP Administration in the Vervet Monkey , 1994 .
[835] B. Fredholm,et al. Deletion of adenosine A1 or A2A receptors reduces l-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease , 2011, Brain Research.
[836] P. De Deurwaerdère,et al. Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brain. , 2013, ACS chemical neuroscience.
[837] T. Napier,et al. Pramipexole-Induced Increased Probabilistic Discounting: Comparison Between a Rodent Model of Parkinson's Disease and Controls , 2012, Neuropsychopharmacology.
[838] S. Garattini,et al. 1-(2-Pyrimidinyl)-piperazine as active metabolite of buspirone in man and rat. , 1986, Pharmacology.
[839] J. Kesslak,et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease , 2001 .
[840] H. Koh,et al. The Roles of Striatal Serotonin and l-Amino-acid Decarboxylase on l-DOPA-induced Dyskinesia in a Hemiparkinsonian Rat Model , 2010, Cellular and Molecular Neurobiology.
[841] Riccardo Viaro,et al. The Nociceptin/Orphanin FQ Receptor Antagonist J-113397 and l-DOPA Additively Attenuate Experimental Parkinsonism through Overinhibition of the Nigrothalamic Pathway , 2007, The Journal of Neuroscience.
[842] M. Sheng,et al. PDZ domain proteins of synapses , 2004, Nature Reviews Neuroscience.
[843] R. Watts,et al. Striatal Overexpression of ΔFosB Reproduces Chronic Levodopa-Induced Involuntary Movements , 2010, The Journal of Neuroscience.
[844] A. Nicholas. Levodopa‐induced hyperactivity in mice treated with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine , 2007, Movement disorders : official journal of the Movement Disorder Society.
[845] P. Jenner,et al. Short and long-term changes in cerebral [14C]-2-deoxyglucose uptake in the MPTP-treated marmoset: relationship to locomotor activity , 2005, Journal of Neural Transmission / General Section JNT.
[846] J. Ahlskog,et al. Levodopa‐dyskinesia incidence by age of Parkinson's disease onset , 2005, Movement disorders : official journal of the Movement Disorder Society.
[847] A. Malhotra,et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[848] J. Dostrovsky,et al. Does stimulation of the GPi control dyskinesia by activating inhibitory axons? , 2001, Movement disorders : official journal of the Movement Disorder Society.
[849] P. Greengard,et al. Beyond the Dopamine Receptor: Review the DARPP-32/Protein Phosphatase-1 Cascade , 1999 .
[850] Charles J. Wilson,et al. RGS4-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion , 2006, Nature Neuroscience.
[851] M. Quik,et al. Nicotine as a potential neuroprotective agent for Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.
[852] C. Barnum,et al. The role of the dorsal raphe nucleus in the development, expression, and treatment of L‐dopa‐induced dyskinesia in hemiparkinsonian rats , 2009, Synapse.
[853] D. Weinberger,et al. BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson’s disease , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.
[854] W. Webb,et al. Lateral motion of fluorescently labeled acetylcholine receptors in membranes of developing muscle fibers. , 1976, Proceedings of the National Academy of Sciences of the United States of America.
[855] Anatol C. Kreitzer,et al. Differential Innervation of Direct- and Indirect-Pathway Striatal Projection Neurons , 2013, Neuron.
[856] Daniel Choquet,et al. Differential activity-dependent regulation of the lateral mobilities of AMPA and NMDA receptors , 2004, Nature Neuroscience.
[857] S. Snyder,et al. Rhes, a striatal–enriched small G–protein, mediates mTOR signaling and L–DOPA–induced dyskinesia , 2011, Nature Neuroscience.
[858] P. Calabresi,et al. Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias , 2012, Neurobiology of Aging.
[859] P. Svenningsson,et al. Striatal Alterations of Secretogranin-1, Somatostatin, Prodynorphin, and Cholecystokinin Peptides in an Experimental Mouse Model of Parkinson Disease*S , 2009, Molecular & Cellular Proteomics.
[860] A. Graybiel,et al. Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis , 2000, Trends in Neurosciences.
[861] J. Brotchie,et al. TC-8831, a nicotinic acetylcholine receptor agonist, reduces l-DOPA-induced dyskinesia in the MPTP macaque , 2013, Neuropharmacology.
[862] J. Bloch,et al. Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons , 2004, Neurobiology of Disease.
[863] J. Yamada,et al. Morphologic changes of dendritic spines of striatal neurons in the levodopa‐induced dyskinesia model , 2014, Movement disorders : official journal of the Movement Disorder Society.
[864] Antonio Cerasa,et al. Increased prefrontal volume in PD with levodopa‐induced dyskinesias: A voxel‐based morphometry study , 2011, Movement disorders : official journal of the Movement Disorder Society.
[865] G. Di Chiara,et al. "Priming" to dopamine agonist-induced contralateral turning as a model of non-associative sensitization to the expression of the post-synaptic dopamine message. , 1993, Behavioural pharmacology.
[866] J. Strachan,et al. α4β2 nicotinic receptors play a role in the nAChR-mediated decline in l-dopa-induced dyskinesias in parkinsonian rats , 2013, Neuropharmacology.
[867] G. Fricchione,et al. Opioid and opiate immunoregulatory processes. , 1996, Critical reviews in immunology.
[868] R. Duvoisin,et al. L-Dopa (L-3,4-dihydroxyphenylanine)--its clinical effects in parkinsonism. , 1968, Transactions of the American Neurological Association.
[869] A. Parent,et al. Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia , 2010, Neurobiology of Disease.
[870] S. Salvadori,et al. Pharmacology of nociceptin and its receptor: a novel therapeutic target , 2000, British journal of pharmacology.
[871] Guo-qiang Lu,et al. Changes in Subcellular Distribution and Phosphorylation of GluR1 in Lesioned Striatum of 6-Hydroxydopamine-Lesioned and l-dopa-Treated Rats , 2006, Neurochemical Research.
[872] M. Collu,et al. 5-Hydroxy-tryptophan for the treatment of l-DOPA-induced dyskinesia in the rat Parkinson's disease model , 2013, Neurobiology of Disease.
[873] J. Brotchie,et al. Fatty Acid Amide Hydrolase (FAAH) Inhibition Reduces l-3,4-Dihydroxyphenylalanine-Induced Hyperactivity in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Non-Human Primate Model of Parkinson's Disease , 2011, Journal of Pharmacology and Experimental Therapeutics.
[874] J. Buccafusco,et al. Desensitization of Nicotinic Acetylcholine Receptors as a Strategy for Drug Development , 2009, Journal of Pharmacology and Experimental Therapeutics.
[875] P. Toro,et al. Addiction to apomorphine: a clinical case-centred discussion. , 2006, Addiction.
[876] Stephen S. G. Ferguson,et al. Synergistic Regulation of β2-Adrenergic Receptor Sequestration: Intracellular Complement of β-Adrenergic Receptor Kinase and β-Arrestin Determine Kinetics of Internalization , 1997 .
[877] S. Fereshtehnejad,et al. Orthostatic Hypotension in Patients with Parkinson's Disease and Atypical Parkinsonism , 2014, Parkinson's disease.
[878] A. Lees,et al. Buspirone in the treatment of levodopa induced dyskinesias. , 1991, Journal of neurology, neurosurgery, and psychiatry.
[879] E. Sinforiani,et al. Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease , 2006, Neurology.
[880] Vsevolod V Gurevich,et al. Regulation of Arrestin Binding by Rhodopsin Phosphorylation Level* , 2007, Journal of Biological Chemistry.
[881] H. Sapru,et al. Overexpression of the dopamine D3 receptor in the rat dorsal striatum induces dyskinetic behaviors , 2014, Behavioural Brain Research.
[882] A. Beckmann,et al. Egr transcription factors in the nervous system , 1997, Neurochemistry International.
[883] Alcino J. Silva,et al. The HMG-CoA Reductase Inhibitor Lovastatin Reverses the Learning and Attention Deficits in a Mouse Model of Neurofibromatosis Type 1 , 2005, Current Biology.
[884] R. Huganir,et al. The cell biology of synaptic plasticity: AMPA receptor trafficking. , 2007, Annual review of cell and developmental biology.
[885] David Garcia-Garcia,et al. Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease. , 2011, Brain : a journal of neurology.
[886] W. Sadee,et al. Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities. , 2005, Life sciences.
[887] M. Quik,et al. The nicotine‐mediated decline in l‐dopa‐induced dyskinesias is associated with a decrease in striatal dopamine release , 2013, Journal of neurochemistry.
[888] P. Calabresi,et al. Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. , 2011, Brain : a journal of neurology.
[889] H. Heinze,et al. Ageing and early-stage Parkinson's disease affect separable neural mechanisms of mesolimbic reward processing. , 2007, Brain : a journal of neurology.
[890] V Sossi,et al. A Reversible Tracer Analysis Approach to the Study of Effective Dopamine Turnover , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[891] C. Marsden,et al. Neurotensin, substance P, delta and mu opioid receptors are decreased in basal ganglia of parkinson's disease patients , 1994, Neuroscience.
[892] L. Lopiano,et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12‐month treatment outcome , 2007, Movement disorders : official journal of the Movement Disorder Society.
[893] N. Quinn. Classification of fluctuations in patients with Parkinson's disease , 1998, Neurology.
[894] J. Cianfrogna,et al. Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator. , 2014, Journal of medicinal chemistry.
[895] Zhenguo Liu,et al. Interactions of CaMKII with dopamine D2 receptors: roles in levodopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's rats , 2014, Scientific Reports.
[896] A. Newman,et al. Evaluation of the D3 dopamine receptor selective antagonist PG01037 on l-dopa-dependent abnormal involuntary movements in rats , 2009, Neuropharmacology.
[897] B. Averbeck,et al. Risk and learning in impulsive and nonimpulsive patients with Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[898] P. Sokoloff,et al. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[899] L. Tremblay,et al. Quantitative analysis of dopaminergic loss in relation to functional territories in MPTP‐treated monkeys , 2003, The European journal of neuroscience.
[900] B. Bioulac,et al. A nationwide survey of excessive daytime sleepiness in Parkinson's disease in France , 2007, Movement disorders : official journal of the Movement Disorder Society.
[901] Erwan Bezard,et al. Enhanced Preproenkephalin-B–Derived Opioid Transmission in Striatum and Subthalamic Nucleus Converges Upon Globus Pallidus Internalis in L-3,4-dihydroxyphenylalanine–Induced Dyskinesia , 2007, Biological Psychiatry.
[902] C. Gerfen,et al. Priming for l-dopa-induced dyskinesia in Parkinson’s disease: A feature inherent to the treatment or the disease? , 2009, Progress in Neurobiology.
[903] S B Dunnett,et al. Behavioural analysis of unilateral monoamine depletion in the marmoset. , 1992, Brain : a journal of neurology.
[904] Robert E. Burke,et al. Pitx3 is required for development of substantia nigra dopaminergic neurons , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[905] J. Volkmann. DEEP BRAIN STIMULATION II Deep Brain Stimulation for the Treatment of Parkinson’s Disease , 2004 .
[906] E. Bézard,et al. Differential behavioral effects of partial bilateral lesions of ventral tegmental area or substantia nigra pars compacta in rats , 2008, Neuroscience.
[907] E. Nestler,et al. Regulators of G-Protein Signaling (RGS) Proteins: Region-Specific Expression of Nine Subtypes in Rat Brain , 1997, The Journal of Neuroscience.
[908] P. Calabresi,et al. Targeting striatal cholinergic interneurons in Parkinson’s disease: Focus on metabotropic glutamate receptors , 2003, Neuropharmacology.
[909] A. Benabid,et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. , 2003, The New England journal of medicine.
[910] M. Mcdermott,et al. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease , 2007, Neurology.
[911] Kwang-Soo Kim,et al. Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson’s disease , 2007, Neurobiology of Disease.
[912] W. Danysz,et al. Pharmacological Modulation of Glutamate Transmission in a Rat Model of l-DOPA-Induced Dyskinesia: Effects on Motor Behavior and Striatal Nuclear Signaling , 2009, Journal of Pharmacology and Experimental Therapeutics.
[913] G. Chiara,et al. Increased striatal expression of glutamate decarboxylase 67 after priming of 6-hydroxydopamine-lesioned rats , 1999, Neuroscience.
[914] A. Triller,et al. The Dynamic Synapse , 2013, Neuron.
[915] J. Girault,et al. Persistent Increase in Olfactory Type G-Protein α Subunit Levels May Underlie D1 Receptor Functional Hypersensitivity in Parkinson Disease , 2004, The Journal of Neuroscience.
[916] Tommaso Pizzorusso,et al. Ras-Guanine Nucleotide-Releasing Factor 1 (Ras-GRF1) Controls Activation of Extracellular Signal-Regulated Kinase (ERK) Signaling in the Striatum and Long-Term Behavioral Responses to Cocaine , 2009, Biological Psychiatry.
[917] J. Brotchie,et al. UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances l-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset , 2014, Neuropharmacology.
[918] J. Villemure,et al. Absence of cholinergic deficits in “pure” vascular dementia , 2005, Neurology.
[919] Y Tateno,et al. Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study. , 1993, Journal of neurology, neurosurgery, and psychiatry.
[920] C. Gerfen,et al. Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[921] Adam T. Brewer,et al. Effects of acute pramipexole on preference for gambling-like schedules of reinforcement in rats , 2010, Psychopharmacology.
[922] P. Calabresi,et al. Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate l-DOPA-induced dyskinesia , 2011, Experimental Neurology.
[923] B. MacVicar,et al. D1 Receptors Physically Interact with N-Type Calcium Channels to Regulate Channel Distribution and Dendritic Calcium Entry , 2008, Neuron.
[924] K. Steece-Collier,et al. Impact of dendritic spine preservation in medium spiny neurons on dopamine graft efficacy and the expression of dyskinesias in parkinsonian rats , 2010, The European journal of neuroscience.
[925] W. Link,et al. DREAM-αCREM Interaction via Leucine-Charged Domains Derepresses Downstream Regulatory Element-Dependent Transcription , 2000, Molecular and Cellular Biology.
[926] Robert Savit,et al. Seizure prediction using scalp electroencephalogram , 2003, Experimental Neurology.
[927] K. Richard Ridderinkhof,et al. The Effect of Parkinson's Disease on the Dynamics of On-line and Proactive Cognitive Control during Action Selection , 2010, Journal of Cognitive Neuroscience.
[928] J. Joyce,et al. Decreased striatal D1 binding density following mesotelencephalic 6-hydroxydopamine injections: an autoradiographic analysis , 1989, Brain Research.
[929] M. Merello,et al. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. , 1999, Clinical neuropharmacology.
[930] J. Sassin,et al. Hyperkinesia and changes in behavior produced in normal monkeys by L‐dopa , 1972, Neurology.
[931] Qin Li,et al. The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model , 2014, Movement disorders : official journal of the Movement Disorder Society.
[932] M. Emborg,et al. Expression of GAD65 and GAD67 immunoreactivity in MPTP-treated monkeys with or without l-DOPA administration , 2005, Neurobiology of Disease.
[933] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[934] Jeffrey S. Stein,et al. Effects of acute pramipexole on male rats' preference for gambling-like rewards II. , 2012, Experimental and clinical psychopharmacology.
[935] Philippe Rostaing,et al. Diffusion Dynamics of Glycine Receptors Revealed by Single-Quantum Dot Tracking , 2003, Science.
[936] P. Calabresi,et al. L‐3,4‐dihydroxyphenylalanine‐induced sprouting of serotonin axon terminals: A useful biomarker for dyskinesias? , 2010, Annals of neurology.
[937] J. Penney,et al. Impact of sustained deprenyl (selegiline) in levodopa‐treated Parkinson's disease: A randomized placebo‐controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial , 2002, Annals of neurology.
[938] M. Quik,et al. Nicotinic Receptor-Mediated Reduction in l-DOPA-Induced Dyskinesias May Occur via Desensitization , 2010, Journal of Pharmacology and Experimental Therapeutics.
[939] P. Calabresi,et al. Targeting metabotropic glutamate receptors as a new strategy against levodopa‐induced dyskinesia in Parkinson's disease? , 2014, Movement disorders : official journal of the Movement Disorder Society.
[940] T. Daigle,et al. A Dopamine D1 Receptor-Dependent β-Arrestin Signaling Complex Potentially Regulates Morphine-Induced Psychomotor Activation but not Reward in Mice , 2011, Neuropsychopharmacology.
[941] Vesna Sossi,et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover , 2001 .
[942] K. Lyons,et al. Efficacy and Tolerability of Levetiracetam in Parkinson Disease Patients With Levodopa-Induced Dyskinesia , 2006, Clinical neuropharmacology.
[943] J. Tesmer,et al. Recognition in the Face of Diversity: Interactions of Heterotrimeric G proteins and G Protein-coupled Receptor (GPCR) Kinases with Activated GPCRs* , 2011, The Journal of Biological Chemistry.
[944] Jie Zhang,et al. The β2-adrenergic receptor/βarrestin complex recruits the clathrin adaptor AP-2 during endocytosis , 1999 .
[945] D. D. Di Monte,et al. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model , 2000, Movement disorders : official journal of the Movement Disorder Society.
[946] M. Cenci,et al. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease , 2011, Neurobiology of Disease.
[947] Y. Goshima,et al. Evidence for l-DOPA systems responsible for cardiovascular control in the nucleus tractus solitarii of the rat , 1992, Neuroscience Letters.
[948] M. Quik,et al. Differential nicotinic receptor expression in monkey basal ganglia: Effects of nigrostriatal damage , 2002, Neuroscience.
[949] Necmettin Yildirim,et al. β2-Adrenergic Receptor Signaling and Desensitization Elucidated by Quantitative Modeling of Real Time cAMP Dynamics* , 2008, Journal of Biological Chemistry.
[950] G. Chiara,et al. Stereospecific blockade of N-methyl-d-aspartate transmission by MK 801 prevents priming of SKF 38393-induced turning , 2005, Psychopharmacology.
[951] Y. Agid,et al. Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease , 2001, Movement disorders : official journal of the Movement Disorder Society.
[952] R. Duvoisin. Cholinergic-anticholinergic antagonism in parkinsonism. , 1967, Archives of neurology.
[953] J. Mink. THE BASAL GANGLIA: FOCUSED SELECTION AND INHIBITION OF COMPETING MOTOR PROGRAMS , 1996, Progress in Neurobiology.
[954] Aaron C. Katzman,et al. Effects of prolonged selective serotonin reuptake inhibition on the development and expression of l-DOPA-induced dyskinesia in hemi-parkinsonian rats , 2014, Neuropharmacology.
[955] R. P. Maguire,et al. Pharmacological and PET studies in patient’s with Parkinson’s disease and a short duration-motor response: implications in the pathophysiology of motor complications , 2004, Journal of Neural Transmission.
[956] S. Haber,et al. Closed-Loop Deep Brain Stimulation Is Superior in Ameliorating Parkinsonism , 2011, Neuron.
[957] N. Mons,et al. Selective expression of one Ca(2+)-inhibitable adenylyl cyclase in dopaminergically innervated rat brain regions. , 1994, Brain research. Molecular brain research.
[958] E. Nestler,et al. ΔFosB Induction in Striatal Medium Spiny Neuron Subtypes in Response to Chronic Pharmacological, Emotional, and Optogenetic Stimuli , 2013, Journal of Neuroscience.
[959] Gilberto Fisone,et al. Increased D1 dopamine receptor signaling in levodopa‐induced dyskinesia , 2005, Annals of neurology.
[960] W. Tourtellotte,et al. The Neuroplasticity-Associated Arc Gene Is a Direct Transcriptional Target of Early Growth Response (Egr) Transcription Factors , 2005, Molecular and Cellular Biology.
[961] Erin M. Schuman,et al. Activity-dependent dynamics and sequestration of proteasomes in dendritic spines , 2006, Nature.
[962] M. Caron,et al. Differential Regulation of the Dopamine D2and D3 Receptors by G Protein-coupled Receptor Kinases and β-Arrestins* , 2001, The Journal of Biological Chemistry.
[963] P. Jenner,et al. Antiparkinsonian activity and dyskinesia risk of ropinirole and L‐DOPA combination therapy in drug naive MPTP‐lesioned common marmosets (Callithrix jacchus) , 2001, Movement disorders : official journal of the Movement Disorder Society.
[964] K. Dalby,et al. Dopamine depletion and subsequent treatment with l‐DOPA, but not the long‐lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum , 2007, Journal of neurochemistry.
[965] C. Benkelfat,et al. The Dopamine Augmenter L-DOPA Does Not Affect Positive Mood in Healthy Human Volunteers , 2012, PloS one.
[966] S. Salvadori,et al. Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide. , 1997, Journal of medicinal chemistry.
[967] U. Dillmann,et al. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. , 2014, Parkinsonism & related disorders.
[968] M. Angela Cenci,et al. cAMP Response Element-Binding Protein Is Required for Dopamine-Dependent Gene Expression in the Intact But Not the Dopamine-Denervated Striatum , 2001, The Journal of Neuroscience.
[969] Erwan Bezard,et al. Levodopa‐induced dyskinesia in MPTP‐treated macaques is not dependent on the extent and pattern of nigrostrial lesioning , 2005, The European journal of neuroscience.
[970] J. Benovic,et al. Reduced expression of G protein-coupled receptor kinases in schizophrenia but not in schizoaffective disorder , 2011, Neurobiology of Disease.
[971] C. Perry. Clinical Features , 2004, Bristol medico-chirurgical journal.
[972] David Eidelberg,et al. Dissociation of Metabolic and Neurovascular Responses to Levodopa in the Treatment of Parkinson's Disease , 2008, The Journal of Neuroscience.
[973] D. Murphy,et al. L-DOPA, catecholamines, and behavior: a clinical and biochemical study in depressed patients. , 1970, Biological psychiatry.
[974] D. Nyholm,et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease , 2005, Neurology.
[975] Philippe Hantraye,et al. Dopamine Gene Therapy for Parkinson’s Disease in a Nonhuman Primate Without Associated Dyskinesia , 2009, Science Translational Medicine.
[976] E. Schuman,et al. Ubiquitin-Mediated Proteasome Activity Is Required for Agonist-Induced Endocytosis of GluRs , 2003, Current Biology.
[977] R. Gainetdinov,et al. The Akt-GSK-3 signaling cascade in the actions of dopamine. , 2007, Trends in pharmacological sciences.
[978] Maurizio Massi,et al. UFP‐112 a Potent and Long‐Lasting Agonist Selective for the Nociceptin/Orphanin FQ Receptor , 2011, CNS neuroscience & therapeutics.
[979] Mikhail N. Koffarnus,et al. Effects of selective dopaminergic compounds on a delay-discounting task , 2011, Behavioural pharmacology.
[980] Bettina Schrader,et al. Two‐year follow‐up of subthalamic deep brain stimulation in Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.
[981] J A Obeso,et al. Preventing levodopa-induced dyskinesias. , 2000, Annals of neurology.
[982] J. Brotchie,et al. L-745,870 Reduces l-DOPA-Induced Dyskinesia in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease , 2012, Journal of Pharmacology and Experimental Therapeutics.
[983] M. Cenci,et al. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW‐6002 in a rat model of l‐DOPA‐induced dyskinesia , 2003, Journal of neurochemistry.
[984] J. Penney,et al. The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.
[985] K. Burchiel,et al. Randomized trial of deep brain stimulation for Parkinson disease , 2012, Neurology.
[986] James Robert Brašić,et al. VMAT2 and dopamine neuron loss in a primate model of Parkinson’s disease , 2008, Journal of neurochemistry.
[987] R. Nicoll,et al. Diversity in NMDA Receptor Composition , 2013, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.
[988] C. Gerfen,et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. , 1990, Science.
[989] R. Hauser,et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations , 2008, Movement disorders : official journal of the Movement Disorder Society.
[990] C. Rebert,et al. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey , 1984, Brain Research.
[991] A. Björklund,et al. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study , 2015, Brain : a journal of neurology.
[992] T. Chase,et al. Glutamate release inhibition ineffective in Levodopa‐induced motor complications , 2006, Movement disorders : official journal of the Movement Disorder Society.
[993] Andreas R. Luft,et al. Dopaminergic Meso-Cortical Projections to M1: Role in Motor Learning and Motor Cortex Plasticity , 2013, Front. Neurol..
[994] G. Brighetti,et al. Prevalence of pathological gambling in patients with Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.
[995] D. Jacobowitz,et al. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[996] Werner Poewe,et al. Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa , 2007, Movement disorders : official journal of the Movement Disorder Society.
[997] Jorge Iriarte,et al. Coupling between Beta and High-Frequency Activity in the Human Subthalamic Nucleus May Be a Pathophysiological Mechanism in Parkinson's Disease , 2010, The Journal of Neuroscience.
[998] Micaela Morelli,et al. Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6‐hydroxydopamine rat model of Parkinson's disease , 2007, Synapse.
[999] Paolo Calabresi,et al. Dopamine-mediated regulation of corticostriatal synaptic plasticity , 2007, Trends in Neurosciences.
[1000] Charles J. Wilson,et al. Spontaneous Activity of Neostriatal Cholinergic Interneurons In Vitro , 1999, The Journal of Neuroscience.
[1001] P. Llorca,et al. Motivational properties of D2 and D3 dopamine receptors agonists and cocaine, but not with D1 dopamine receptors agonist and l-dopa, in bilateral 6-OHDA-lesioned rat , 2013, Neuropharmacology.
[1002] S. Varanese,et al. NMDA antagonist memantine improves levodopa‐induced dyskinesias and “On‐off” phenomena in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[1003] V. Voon,et al. Pharmacological characterization of psychosis‐like behavior in the MPTP‐lesioned nonhuman primate model of Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.
[1004] M. Palkovits,et al. Distribution of nociceptin/orphanin FQ in adult human brain , 2004, Brain Research.
[1005] A. Lawrence,et al. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease , 2005, Neurology.
[1006] A. Dagher,et al. Amphetamine-Induced Increases in Extracellular Dopamine, Drug Wanting, and Novelty Seeking: A PET/[11C]Raclopride Study in Healthy Men , 2002, Neuropsychopharmacology.
[1007] L. Grégoire,et al. mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys , 2008, Neurobiology of Aging.
[1008] P. Worley,et al. Immediate-Early Genes and Synaptic Function , 1998, Neurobiology of Learning and Memory.
[1009] Micaela Morelli,et al. Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions , 1994, Trends in Neurosciences.
[1010] E M Ross,et al. GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. , 2000, Annual review of biochemistry.
[1011] P. Brundin,et al. The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat , 2006, Neurobiology of Disease.
[1012] G. Chiara,et al. Behavioural sensitization in 6-hydroxydopamine lesioned rats involves the dopamine signal transduction: Changes in DARPP-32 phosphorylation , 1994, Neuroscience.
[1013] R. Palmiter,et al. Induction of stereotypy in dopamine-deficient mice requires striatal D1 receptor activation , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[1014] B. Bioulac,et al. Serotonergic neurons mediate ectopic release of dopamine induced by l-DOPA in a rat model of Parkinson's disease , 2010, Neurobiology of Disease.
[1015] A. Björklund,et al. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons , 2012, Neurobiology of Disease.
[1016] E. Storey,et al. Influence of Single Nucleotide Polymorphisms in COMT, MAO-A and BDNF Genes on Dyskinesias and Levodopa Use in Parkinson's Disease , 2013, Neurodegenerative Diseases.
[1017] MK‐801 alters the effects of priming with L‐DOPA on dopamine D1 receptor‐induced changes in neuropeptide mRNA levels in the rat striatal output neurons , 2002, Synapse.
[1018] A. Sampson,et al. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models , 2006, Nature Neuroscience.
[1019] S. Sarubbo,et al. Brain Interstitial Nociceptin/Orphanin FQ Levels are Elevated in Parkinson's Disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[1020] L. Rumbach,et al. Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson's disease: involvement of l-dopa therapy , 2004, Autonomic Neuroscience.
[1021] F. Zhou,et al. Parallel dopamine D1 receptor activity dependence of l-Dopa-induced normal movement and dyskinesia in mice , 2013, Neuroscience.
[1022] Johannes Schwarz,et al. D2 Dopamine Receptors Colocalize Regulator of G-Protein Signaling 9-2 (RGS9-2) via the RGS9 DEP Domain, and RGS9 Knock-Out Mice Develop Dyskinesias Associated with Dopamine Pathways , 2005, The Journal of Neuroscience.
[1023] P. Ballard,et al. Parkinsonism Induced By 1-Methyl-4-Phenyl-1, 2, 3, 6-Tetrahydropyridine (MPTP): Implications for Treatment and the Pathogenesis of Parkinson’s Disease , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[1024] Regina Katzenschlager,et al. Punding in Parkinson's disease: Its relation to the dopamine dysregulation syndrome , 2004, Movement disorders : official journal of the Movement Disorder Society.
[1025] A. Gobert,et al. α2‐Adrenergic Receptor Blockade Markedly Potentiates Duloxetine‐ and Fluoxetine‐Induced Increases in Noradrenaline, Dopamine, and Serotonin Levels in the Frontal Cortex of Freely Moving Rats , 1997 .
[1026] R. Barker,et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial , 2014, The Lancet.
[1027] E. Hirsch,et al. Evidence for a dopaminergic innervation of the pedunculopontine nucleus in monkeys, and its drastic reduction after MPTP intoxication , 2009, Journal of neurochemistry.
[1028] M. Hutz,et al. DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients. , 2012, Pharmacogenomics.
[1029] G F Koob,et al. Drug abuse: hedonic homeostatic dysregulation. , 1997, Science.
[1030] H. Bengtsson,et al. Serotonin autoreceptor function and antidepressant drug action , 2000, Journal of psychopharmacology.
[1031] R. Hauser,et al. Open‐label pilot study of levetiracetam (Keppra) for the treatment of levodopa‐induced dyskinesias in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.
[1032] P. De Deurwaerdère,et al. Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia , 2011, Parkinson's disease.
[1033] Antoine Triller,et al. Synaptic stability and plasticity in a floating world , 2010, Current Opinion in Neurobiology.
[1034] O. Rascol,et al. Clozapine improves dyskinesias in Parkinson disease , 2004, Neurology.
[1035] E. Nestler,et al. Induction of Activating Transcription Factors (ATFs) ATF2, ATF3, and ATF4 in the Nucleus Accumbens and Their Regulation of Emotional Behavior , 2008, The Journal of Neuroscience.
[1036] A. Giuditta,et al. Protein-synthesizing machinery in the axon compartment , 1999, Neuroscience.
[1037] D. Mash,et al. Dopamine D1 receptor expression in human basal ganglia and changes in Parkinson's disease , 2001 .
[1038] E. Bézard,et al. Pharmacological Analysis Demonstrates Dramatic Alteration of D1 Dopamine Receptor Neuronal Distribution in the Rat Analog of l-DOPA-Induced Dyskinesia , 2009, The Journal of Neuroscience.
[1039] J. Langston,et al. Investigating levodopa-induced dyskinesias in the parkinsonian primate. , 2000, Annals of neurology.
[1040] K. Dalby,et al. Overexpression of GRK6 rescues l-DOPA-induced signaling abnormalities in the dopamine-depleted striatum of hemiparkinsonian rats , 2015, Experimental Neurology.
[1041] C. Tanner,et al. Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study) , 2015, Movement disorders : official journal of the Movement Disorder Society.
[1042] M. Rizzone,et al. 80 Hz versus 130 Hz subthalamic nucleus deep brain stimulation: effects on involuntary movements. , 2013, Parkinsonism & related disorders.
[1043] A. Björklund,et al. Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model , 2009, Experimental Neurology.
[1044] L. Schiffer,et al. Aromatic amino acids and modification of parkinsonism. , 1967, The New England journal of medicine.
[1045] P. Greengard,et al. l‐DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice , 2009, Journal of neurochemistry.
[1046] Andreea C. Bostan,et al. The basal ganglia communicate with the cerebellum , 2010, Proceedings of the National Academy of Sciences.
[1047] T. Roth,et al. Sleepiness in Parkinson's disease: A controlled study , 2003, Movement disorders : official journal of the Movement Disorder Society.
[1048] W. Danysz,et al. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease , 2006, Brain Research Bulletin.
[1049] M. Onofrj,et al. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. , 2004, Journal of neurology, neurosurgery, and psychiatry.
[1050] E. Bézard,et al. Molecular mechanisms of l-DOPA-induced dyskinesia. , 2011, International review of neurobiology.
[1051] P. Ravenscroft,et al. Calcium‐permeable AMPA receptors are involved in the induction and expression of l‐DOPA‐induced dyskinesia in Parkinson’s disease , 2010, Journal of neurochemistry.
[1052] P. Spano,et al. Regulation of Dopamine D1 Receptor Trafficking and Desensitization by Oligomerization with Glutamate N-Methyl-D-aspartate Receptors* , 2003, Journal of Biological Chemistry.
[1053] W. Koch,et al. Myocardial overexpression of GRK3 in transgenic mice: evidence for in vivo selectivity of GRKs. , 1998, American journal of physiology. Heart and circulatory physiology.
[1054] D. Riche,et al. Riluzole Reduces Incidence of Abnormal Movements but Not Striatal Cell Death in a Primate Model of Progressive Striatal Degeneration , 1997, Experimental Neurology.
[1055] B Bioulac,et al. Reversal of Rigidity and Improvement in Motor Performance by Subthalamic High‐frequency Stimulation in MPTP‐treated Monkeys , 1993, The European journal of neuroscience.
[1056] R. Roth,et al. Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus) , 1997, Neuroscience.
[1057] Qin Li,et al. Selective Inactivation of Striatal FosB/ΔFosB-Expressing Neurons Alleviates L-DOPA–Induced Dyskinesia , 2016, Biological Psychiatry.
[1058] D. Choquet,et al. Regulation of AMPA receptor lateral movements , 2002, Nature.
[1059] Qin Li,et al. l-DOPA Impairs Proteasome Activity in Parkinsonism through D1 Dopamine Receptor , 2012, The Journal of Neuroscience.
[1060] Jee-Young Lee,et al. Differential genetic susceptibility in diphasic and peak‐dose dyskinesias in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[1061] S. Liggett,et al. Phosphorylation Barcoding as a Mechanism of Directing GPCR Signaling , 2011, Science Signaling.
[1062] R. Veh,et al. Individual neurons in the rat lateral habenular complex project mostly to the dopaminergic ventral tegmental area or to the serotonergic raphe nuclei , 2012, The Journal of comparative neurology.
[1063] P. Greengard,et al. Dopamine- and cAMP-regulated Phosphoprotein of 32-kDa (DARPP-32)-dependent Activation of Extracellular Signal-regulated Kinase (ERK) and Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling in Experimental Parkinsonism* , 2012, The Journal of Biological Chemistry.
[1064] Y. Agid,et al. Low-dose clozapine improves dyskinesias in Parkinson's disease , 1997, Neurology.
[1065] J. Kordower,et al. Primate models of Parkinson’s disease , 2003, Experimental Neurology.
[1066] M. Beal,et al. Chronic 3-Nitropropionic Acid Treatment in Baboons Replicates the Cognitive and Motor Deficits of Huntington’s Disease , 1996, The Journal of Neuroscience.
[1067] R. Palmiter,et al. Restoration of dopamine signaling to the dorsal striatum is sufficient for aspects of active maternal behavior in female mice. , 2013, Endocrinology.
[1068] E. López‐Valdés,et al. Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.
[1069] P. Cohen. Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.
[1070] V. Sossi,et al. Increase in Dopamine Turnover Occurs Early in Parkinson's Disease: Evidence from a New Modeling Approach to PET 18F-Fluorodopa Data , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[1071] B Anton,et al. Immunohistochemical localization of ORL‐1 in the central nervous system of the rat , 1996, The Journal of comparative neurology.
[1072] J. Surmeier,et al. Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models , 2014, Neurobiology of Disease.
[1073] A. Björklund,et al. Involvement of the serotonin system in L-dopa-induced dyskinesias. , 2008, Parkinsonism & related disorders.
[1074] Qin Li,et al. L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum , 2014, Scientific Reports.
[1075] J. Deniau,et al. Synaptic Convergence of Motor and Somatosensory Cortical Afferents onto GABAergic Interneurons in the Rat Striatum , 2002, Journal of Neuroscience.
[1076] J. Nutt,et al. Effects of a NR2B selective NMDA glutamate antagonist, CP‐101,606, on dyskinesia and parkinsonism , 2008, Movement disorders : official journal of the Movement Disorder Society.
[1077] Anders Björklund,et al. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. , 2007, Brain : a journal of neurology.
[1078] C. Waters,et al. Compulsive eating and weight gain related to dopamine agonist use , 2006, Movement disorders : official journal of the Movement Disorder Society.
[1079] R. Lefkowitz,et al. Different G protein-coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 vasopressin receptor. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[1080] L. Verhagen Metman,et al. Internal pallidal neuronal activity during mild drug-related dyskinesias in Parkinson's disease: decreased firing rates and altered firing patterns. , 2007, Journal of neurophysiology.
[1081] S. Grant,et al. Inhibition of the Dopamine D1 Receptor Signaling by PSD-95*♦ , 2007, Journal of Biological Chemistry.
[1082] S. Watson,et al. Localization of orphanin FQ (nociceptin) peptide and messenger RNA in the central nervous system of the rat , 1999, The Journal of comparative neurology.
[1083] B. Balleine,et al. The role of the dorsomedial striatum in instrumental conditioning , 2005, The European journal of neuroscience.
[1084] Qin Li,et al. A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys , 2010, Neurobiology of Disease.
[1085] M. Savasta,et al. Different plasticity changes in D1 and D2 receptors in rat striatal subregions following impairment of dopaminergic transmission , 1988, Neuroscience Letters.
[1086] A. Björklund,et al. Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease , 2012, Neurobiology of Disease.
[1087] V. Sossi,et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease , 2000, Annals of neurology.
[1088] J. Brotchie,et al. Non‐subtype‐selective opioid receptor antagonism in treatment of levodopa‐induced motor complications in Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.
[1089] R. Tsien,et al. The Fluorescent Toolbox for Assessing Protein Location and Function , 2006, Science.
[1090] J. Changeux. Allosteric receptors: from electric organ to cognition. , 2010, Annual review of pharmacology and toxicology.
[1091] L. Grégoire,et al. Effect of a selective glutamate antagonist on l-dopa-induced dyskinesias in drug-naive parkinsonian monkeys , 2004, Neurobiology of Disease.
[1092] Marc G Caron,et al. DDD mice, a novel acute mouse model of Parkinson’s disease , 2006, Neurology.
[1093] O. Blin,et al. Levodopa-induced Drowsiness in Healthy Volunteers: Results of a Choice Reaction Time Test Combined with a Subjective Evaluation of Sedation , 2001, Clinical neuropharmacology.
[1094] L. Defebvre,et al. Reduced levodopa-induced complications after 5 years of subthalamic stimulation in Parkinson’s disease: a second honeymoon , 2009, Journal of Neurology.
[1095] P. Calabresi,et al. Nociceptin/Orphanin FQ Receptor Agonists Attenuate l-DOPA-Induced Dyskinesias , 2012, The Journal of Neuroscience.
[1096] J D Corbit,et al. An opponent-process theory of motivation. II. Cigarette addiction. , 1973, Journal of abnormal psychology.
[1097] Johannes Schwarz,et al. RGS9 Modulates Dopamine Signaling in the Basal Ganglia , 2003, Neuron.
[1098] O. Rascol,et al. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. , 2014, Parkinsonism & related disorders.
[1099] R Barber,et al. Repetitive endocytosis and recycling of the beta 2-adrenergic receptor during agonist-induced steady state redistribution. , 1996, Molecular pharmacology.
[1100] H. Steinbusch,et al. Inhibition of 5-HT neuron activity and induction of depressive-like behavior by high-frequency stimulation of the subthalamic nucleus , 2007, Proceedings of the National Academy of Sciences.
[1101] K. Elisabet Ohlin,et al. Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease , 2012, NeuroImage.
[1102] E. Bézard,et al. High frequency stimulation of the internal Globus Pallidus (GPi) simultaneously improves parkinsonian symptoms and reduces the firing frequency of GPi neurons in the MPTP-treated monkey , 1996, Neuroscience Letters.
[1103] J. Jankovic,et al. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. , 2014, Parkinsonism & related disorders.
[1104] G. Fisone,et al. Psychoactive drugs and regulation of the cAMP/PKA/DARPP-32 cascade in striatal medium spiny neurons , 2007, Neuroscience & Biobehavioral Reviews.
[1105] J. Obeso,et al. Successful thalamic deep brain stimulation for orthostatic tremor , 2008, Movement disorders : official journal of the Movement Disorder Society.
[1106] S. Konitsiotis,et al. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys , 2000, Neurology.
[1107] J. McGinty,et al. RGS4 overexpression in the rat dorsal striatum modulates mGluR5- and amphetamine-mediated behavior and signaling , 2011, Psychopharmacology.
[1108] C. N. Homann,et al. Experience, competency, and education: Graduating neurology residents’ experience with tPA , 2001, Neurology.
[1109] A. Björklund,et al. The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation , 2014, Neurobiology of Disease.
[1110] M. Okun,et al. Unilateral GPi-DBS as a Treatment for Levodopa-Induced Respiratory Dyskinesia in Parkinson Disease , 2011, The neurologist.
[1111] J. Maloteaux,et al. Opposite modulation of regulators of G protein signalling-2 (RGS2) and RGS4 expression by dopamine receptors in the rat striatum , 2002, Neuroscience Letters.
[1112] E. Bézard,et al. Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over ("n-of-1") exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients. , 2013, Parkinsonism & related disorders.
[1113] A. Nambu. Seven problems on the basal ganglia , 2008, Current Opinion in Neurobiology.
[1114] S. Grady,et al. Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice. , 2013, Biochemical pharmacology.
[1115] M. Bencherif,et al. Nicotinic Receptor Agonists Reduce l-DOPA–Induced Dyskinesias in a Monkey Model of Parkinson's Disease , 2013, The Journal of Pharmacology and Experimental Therapeutics.
[1116] Marc G Caron,et al. Desensitization of G protein-coupled receptors and neuronal functions. , 2004, Annual review of neuroscience.
[1117] A. Lang,et al. The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[1118] M. Geffard,et al. The metabolism of exogenous L-Dopa in the brain: An immunohistochemical study of its conversion to dopamine in non-catecholaminergic cells of the rat brain , 1991, Journal of neural transmission. Parkinson's disease and dementia section.
[1119] Henrik Alm,et al. Normalization and expression changes in predefined sets of proteins using 2D gel electrophoresis: A proteomic study of L-DOPA induced dyskinesia in an animal model of Parkinson's disease using DIGE , 2006, BMC Bioinformatics.
[1120] G. Fisone,et al. mTORC1 signaling in Parkinson disease and L-DOPA-induced dyskinesia: A sensitized matter , 2010, Cell cycle.
[1121] G. Robertson,et al. D1-Receptor-related priming is attenuated by antisense-meditated 'knockdown' of fosB expression. , 1998, Brain research. Molecular brain research.
[1122] Rui M. Costa,et al. Rapid Alterations in Corticostriatal Ensemble Coordination during Acute Dopamine-Dependent Motor Dysfunction , 2006, Neuron.
[1123] W. Danysz,et al. Proteomic analysis of striatal proteins in the rat model of l‐DOPA‐induced dyskinesia , 2007, Journal of neurochemistry.
[1124] T. Chase,et al. Milacemide therapy for Parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.
[1125] S. Dunnett,et al. Behavioral analysis of motor and non-motor symptoms in rodent models of Parkinson's disease. , 2010, Progress in brain research.
[1126] A. Rajput,et al. Tolcapone improves motor function in parkinsonian patients with the"wearing-off" phenomenon: A double-blind, placebo-controlled, multicenter trial , 1997, Neurology.
[1127] V. Gurevich,et al. Dopamine Receptors and the Treatment of Parkinson's Disease , 2010 .
[1128] M. Barrot,et al. DeltaFosB: a sustained molecular switch for addiction. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[1129] R. Moratalla,et al. Genetic Inactivation of Dopamine D1 but Not D2 Receptors Inhibits L-DOPA–Induced Dyskinesia and Histone Activation , 2009, Biological Psychiatry.
[1130] P. Blanchet,et al. Molecular basis of levodopa-induced dyskinesias. , 2000, Annals of neurology.
[1131] Qin Li,et al. Distinct Changes in cAMP and Extracellular Signal-Regulated Protein Kinase Signalling in L-DOPA-Induced Dyskinesia , 2010, PloS one.
[1132] S. Dunnett,et al. Comparison of rating scales used to evaluate l-DOPA-induced dyskinesia in the 6-OHDA lesioned rat , 2013, Neurobiology of Disease.
[1133] Ulf Bömer,et al. High‐Throughput Screening for Kinase Inhibitors , 2005, Chembiochem : a European journal of chemical biology.
[1134] D. James Surmeier,et al. Re-emergence of striatal cholinergic interneurons in movement disorders , 2007, Trends in Neurosciences.
[1135] P. Greengard,et al. Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in l-DOPA treatment of an animal model of Parkinsonism , 2008, Proceedings of the National Academy of Sciences.
[1136] E. Roubos,et al. The gray area between synapse structure and function—Gray's synapse types I and II revisited , 2011, Synapse.
[1137] E. Bézard,et al. Levetiracetam Potentiates the Antidyskinetic Action of Amantadine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-Lesioned Primate Model of Parkinson's Disease , 2004, Journal of Pharmacology and Experimental Therapeutics.
[1138] A. Lees,et al. Idazoxan is ineffective for levodopa‐induced dyskinesias in Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.
[1139] A. Schapira,et al. Test for LRRK2 mutations in patients with Parkinson’s disease , 2008, Practical Neurology.
[1140] Paul Greengard,et al. Critical Involvement of cAMP/DARPP-32 and Extracellular Signal-Regulated Protein Kinase Signaling in l-DOPA-Induced Dyskinesia , 2007, The Journal of Neuroscience.
[1141] L Teare,et al. Cannabis for dyskinesia in Parkinson disease , 2004, Neurology.
[1142] D. Balfour,et al. Nicotine: from molecular mechanisms to behaviour. , 2005, Current opinion in pharmacology.
[1143] S. Wonnacott,et al. alpha-bungarotoxin-sensitive nicotinic receptors indirectly modulate [(3)H]dopamine release in rat striatal slices via glutamate release. , 2000, Molecular pharmacology.
[1144] T. Matsuda,et al. Neuronal nitric oxide synthase inhibition attenuates the development of L-DOPA-induced dyskinesia in hemi-Parkinsonian rats. , 2012, European journal of pharmacology.
[1145] John Seibyl,et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. , 2004, Archives of neurology.
[1146] G. Arbuthnott,et al. Plasticity of Synapses in the Rat Neostriatum after Unilateral Lesion of the Nigrostriatal Dopaminergic Pathway , 1998, The Journal of Neuroscience.
[1147] E. Bézard,et al. Dopamine receptors and L-dopa-induced dyskinesia. , 2009, Parkinsonism & related disorders.
[1148] R. Djaldetti,et al. Riluzole for le vodopa-induced dyskinesias in advanced P arkinson's disease , 1999, The Lancet.
[1149] P. Calabresi,et al. A Critical Interaction between NR2B and MAGUK in l-DOPA Induced Dyskinesia , 2006, The Journal of Neuroscience.
[1150] M. Hornberger,et al. Screening for impulse control symptoms in patients with de novo Parkinson disease: A case-control study , 2013, Neurology.
[1151] S. Shapiro. ALLOPURINOL AND BONE-MARROW DEPRESSION , 1974 .
[1152] C. Olanow,et al. Modeling Parkinson's disease , 2009, Annals of neurology.
[1153] R. Eglen,et al. Drug discovery and the human kinome: recent trends. , 2011, Pharmacology & therapeutics.
[1154] P. Calabresi,et al. Permissive role of interneurons in corticostriatal synaptic plasticity , 1999, Brain Research Reviews.
[1155] K. Saitoh,et al. Basal ganglia efferents to the brainstem centers controlling postural muscle tone and locomotion: a new concept for understanding motor disorders in basal ganglia dysfunction , 2003, Neuroscience.
[1156] A. Benabid,et al. Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson's disease , 1997, The Lancet.
[1157] D. Erlij,et al. 6-OHDA-induced hemiparkinsonism and chronic l-DOPA treatment increase dopamine D1-stimulated [3H]-GABA release and [3H]-cAMP production in substantia nigra pars reticulata of the rat , 2008, Neuropharmacology.
[1158] T. Deak,et al. Contribution of the striatum to the effects of 5‐HT1A receptor stimulation in L‐DOPA‐treated hemiparkinsonian rats , 2009, Journal of neuroscience research.